SelectQuote (SLQT) 10-Q 14 Feb 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2021	Jan. 31, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-39295
Entity Registrant Name	SelectQuote, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3339273
Entity Address, Address Line One	6800 West 115th Street
Entity Address, Address Line Two	Suite 2511
Entity Address, City or Town	Overland Park
Entity Address, State or Province	KS
Entity Address, Postal Zip Code	66211
City Area Code	913
Local Phone Number	599-9225
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	SLQT
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		164,017,054
Entity Central Index Key	0001794783
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Jun. 30, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 193,357	$ 286,454
Accounts receivable	149,399	105,298
Commissions receivable-current	202,289	89,120
Other current assets	10,511	4,486
Total current assets	555,556	485,358
COMMISSIONS RECEIVABLE—Net	683,516	756,777
PROPERTY AND EQUIPMENT—Net	42,676	29,510
SOFTWARE—Net	15,009	12,611
OPERATING LEASE RIGHT-OF-USE ASSETS	30,571	31,414
INTANGIBLE ASSETS—Net	37,727	40,670
GOODWILL	73,732	68,019
OTHER ASSETS	6,046	1,436
TOTAL ASSETS	1,444,833	1,425,795
CURRENT LIABILITIES:
Accounts payable	47,579	34,079
Accrued expenses	22,904	20,676
Accrued compensation and benefits	43,384	40,909
Operating lease liabilities—current	5,251	5,289
Current portion of long-term debt	7,169	2,360
Other current liabilities	9,120	5,504
Total current liabilities	135,407	108,817
LONG-TERM DEBT, NET—less current portion	700,350	459,043
Deferred income taxes	76,942	139,240
OPERATING LEASE LIABILITIES	36,951	38,392
OTHER LIABILITIES	2,779	11,743
Total liabilities	952,429	757,235
COMMITMENTS AND CONTINGENCIES (Note 8)
SHAREHOLDERS’ EQUITY:
Common stock, $0.01 par value	1,640	1,635
Additional paid-in capital	551,002	544,771
Retained earnings (accumulated deficit)	(62,236)	121,925
Accumulated other comprehensive income	1,998	229
Total shareholders’ equity	492,404	668,560
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 1,444,833	$ 1,425,795

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Jun. 30, 2021
Statement of Financial Position [Abstract]
Common stock, par value, (dollars per share)	$ 0.01	$ 0.01

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
REVENUE:
Total revenue	$ 194,981	$ 357,565	$ 352,508	$ 480,339
OPERATING COSTS AND EXPENSES:
Cost of revenue	148,108	84,121	240,273	135,166
Marketing and advertising	193,246	132,206	283,923	182,006
General and administrative	20,147	13,043	43,539	25,245
Technical development	6,386	4,750	12,239	8,598
Total operating costs and expenses	367,887	234,120	579,974	351,015
INCOME (LOSS) FROM OPERATIONS	(172,906)	123,445	(227,466)	129,324
INTEREST EXPENSE, NET	(10,587)	(6,782)	(19,122)	(13,543)
OTHER EXPENSES, NET	(51)	(416)	(153)	(1,196)
INCOME (LOSS) BEFORE INCOME TAX EXPENSE (BENEFIT)	(183,544)	116,247	(246,741)	114,585
Income Tax Expense (Benefit)	(46,536)	26,391	(62,580)	24,994
NET INCOME (LOSS)	$ (137,008)	$ 89,856	$ (184,161)	$ 89,591
NET INCOME (LOSS) PER SHARE:
Basic (in dollars per share)	$ (0.84)	$ 0.55	$ (1.12)	$ 0.55
Diluted (in dollars per share)	$ (0.84)	$ 0.54	$ (1.12)	$ 0.54
WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:
Basic (in shares)	163,966	162,645	163,829	162,546
Diluted (in shares)	163,966	165,563	163,829	165,377
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:
Gain (loss) on cash flow hedge	$ 1,775	$ 116	$ 1,769	$ (141)
OTHER COMPREHENSIVE INCOME (LOSS)	1,775	116	1,769	(141)
COMPREHENSIVE INCOME (LOSS)	(135,233)	89,972	(182,392)	89,450
Commission
REVENUE:
Total revenue	140,701	320,265	272,956	425,415
Production bonus and other
REVENUE:
Total revenue	$ 54,280	$ 37,300	$ 79,552	$ 54,924

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Restricted Stock Units (RSUs)	Common Stock	Common StockRestricted Stock Units (RSUs)	Additional Paid-In Capital	Additional Paid-In CapitalRestricted Stock Units (RSUs)	Retained Earnings/(Accumulated Deficit)	Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Jun. 30, 2020			162,191,000
Beginning balance at Jun. 30, 2020	$ 544,186		$ 1,622		$ 548,113		$ (4,295)	$ (1,254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	89,591						89,591
Gain on cash flow hedge, net of tax	(375)							(375)
Amount reclassified into earnings, net of tax	234							234
Stock options exercised (in shares)			583,000
Stock options exercised	(4,906)		$ 6		(4,912)
Share-based compensation expense	2,240				2,240
Ending balance (in shares) at Dec. 31, 2020			162,774,000
Ending balance at Dec. 31, 2020	630,970		$ 1,628		545,441		85,296	(1,395)
Beginning balance (in shares) at Jun. 30, 2020			162,191,000
Beginning balance at Jun. 30, 2020	544,186		$ 1,622		548,113		(4,295)	(1,254)
Ending balance (in shares) at Jun. 30, 2021			163,510,000
Ending balance at Jun. 30, 2021	668,560		$ 1,635		544,771		121,925	229
Beginning balance (in shares) at Sep. 30, 2020			162,507,000
Beginning balance at Sep. 30, 2020	542,369		$ 1,625		546,815		(4,560)	(1,511)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	89,856						89,856
Gain on cash flow hedge, net of tax	0							0
Amount reclassified into earnings, net of tax	116							116
Stock options exercised (in shares)			267,000
Stock options exercised	(2,707)		$ 3		(2,710)
Share-based compensation expense	1,336				1,336
Ending balance (in shares) at Dec. 31, 2020			162,774,000
Ending balance at Dec. 31, 2020	630,970		$ 1,628		545,441		85,296	(1,395)
Beginning balance (in shares) at Jun. 30, 2021			163,510,000
Beginning balance at Jun. 30, 2021	668,560		$ 1,635		544,771		121,925	229
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(47,153)
Ending balance (in shares) at Sep. 30, 2021			163,930,000
Ending balance at Sep. 30, 2021	625,668		$ 1,639		549,034		74,772	223
Beginning balance (in shares) at Jun. 30, 2021			163,510,000
Beginning balance at Jun. 30, 2021	668,560		$ 1,635		544,771		121,925	229
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(184,161)						(184,161)
Gain on cash flow hedge, net of tax	1,423							1,423
Amount reclassified into earnings, net of tax	$ 346							346
Stock options exercised (in shares)	339,670		339,000
Stock options exercised	$ 1,282		$ 3		1,279
Issuance of common stock pursuant to employee stock purchase plan (in shares)			90,000
Issuance of common stock pursuant to employee stock purchase plan and vesting of restricted stock unit awards	989		$ 1		988
Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings (in shares)				74,000
Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings		$ (144)	$ 1			$ (145)
Share-based compensation expense	4,109				4,109
Ending balance (in shares) at Dec. 31, 2021			164,013,000
Ending balance at Dec. 31, 2021	492,404		$ 1,640		551,002		(62,236)	1,998
Beginning balance (in shares) at Sep. 30, 2021			163,930,000
Beginning balance at Sep. 30, 2021	625,668		$ 1,639		549,034		74,772	223
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(137,008)						(137,008)
Gain on cash flow hedge, net of tax	1,602							1,602
Amount reclassified into earnings, net of tax	173							173
Stock options exercised (in shares)			55,000
Stock options exercised	76		$ 0		76
Issuance of common stock pursuant to employee stock purchase plan (in shares)			0
Issuance of common stock pursuant to employee stock purchase plan and vesting of restricted stock unit awards	0		$ 0		0
Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings (in shares)				28,000
Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings		$ (1)		$ 1		$ (2)
Share-based compensation expense	1,894				1,894
Ending balance (in shares) at Dec. 31, 2021			164,013,000
Ending balance at Dec. 31, 2021	$ 492,404		$ 1,640		$ 551,002		$ (62,236)	$ 1,998

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (137,008)	$ (47,153)	$ 89,856	$ (184,161)	$ 89,591
Adjustments to reconcile net income (loss) to net cash, cash equivalents, and restricted cash used in operating activities:
Depreciation and amortization				11,278	6,937
Loss on disposal of property, equipment, and software	5		79	355	162
Share-based compensation expense				4,109	2,259
Deferred income taxes				(62,940)	24,879
Amortization of debt issuance costs and debt discount				2,974	1,644
Fair value adjustments to contingent earnout obligations			395	0	1,153
Non-cash lease expense				2,040	1,887
Changes in operating assets and liabilities:
Accounts receivable				(43,429)	(61,251)
Commissions receivable				(39,908)	(219,132)
Other assets				(5,555)	1,906
Accounts payable and accrued expenses				15,135	15,692
Operating lease liabilities				(2,676)	(1,245)
Other liabilities				(2,963)	32,370
Net cash used in operating activities				(305,741)	(103,148)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment				(17,904)	(5,768)
Purchases of software and capitalized software development costs				(5,231)	(3,449)
Acquisition of business				(6,927)	121
Investment in equity securities				(1,000)	0
Net cash used in investing activities				(31,062)	(9,096)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit				50,000	0
Payments on revolving line of credit				(50,000)	0
Net proceeds from Term Loans				242,000	0
Payments on other debt				(93)	(108)
Proceeds from common stock options exercised and employee stock purchase plan	100		100	2,271	391
Payments of tax withholdings related to net share settlement of equity awards				(144)	(5,320)
Payments of debt issuance costs				(328)	0
Net cash provided by financing activities				243,706	(10,719)
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH				(93,097)	(122,963)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—Beginning of period		$ 286,454		286,454	368,870	$ 368,870
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—End of period	193,357		245,907	193,357	245,907	286,454
Reconciliation to the Consolidated Balance Sheets:
Cash and cash equivalents	193,357		209,739	193,357	209,739	286,454
Restricted cash	0		36,168	0	36,168
Total cash, cash equivalents, and restricted cash	$ 193,357		$ 245,907	193,357	245,907	$ 286,454
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid, net				(15,447)	(11,953)
Income taxes paid, net				(19)	(86)
Private Placement
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of stock issuance costs				0	(1,771)
IPO
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of stock issuance costs				$ 0	$ (3,911)

Summary of Business and Signifi

Summary of Business and Significant Accounting Policies	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Business and Significant Accounting Policies	SUMMARY OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES Description of Business —SelectQuote, Inc. (together with its subsidiaries, the “Company” or “SelectQuote”) contracts with insurance carriers to sell senior health, life, and auto and home insurance policies by telephone to individuals throughout the United States through the use of multi-channel marketing and advertising campaigns. The Company obtains leads from, among other sources, InsideResponse, a wholly-owned subsidiary that provides sales leads to the consumer insurance industry. The Company also coordinates various healthcare-related services through its Population Health platform, which includes SelectRx, a closed-door, long-term care pharmacy that offers pharmacy services, including essential prescription medications, OTC medications, customized medication packaging, medication therapy management, and other consultative services under the Patient Centered Pharmacy Home (PCPH) model. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products, and along with Population Health and InsideResponse, is referred to as “Senior”. SelectQuote’s Life division (“Life”) sells term life, final expense, and other ancillary products, and SelectQuote’s Auto & Home division (“Auto & Home”) primarily sells non-commercial auto and home property and casualty insurance products. SelectQuote’s licensed insurance agents provide comparative rates from a variety of insurance carriers relying on our technology distribution channel with a combination of proprietary and commercially available software to perform its quote service and sell insurance policies on behalf of the insurance carriers. The Company primarily earns revenue in the form of commission payments from the insurance carriers. Commission payments are received both when the initial policy is sold (“first year”) and when the underlying policyholder renews their policy in subsequent years (“renewal”). The Company also receives certain volume-based bonuses from some carriers on first-year policies sold based on attaining various predetermined target sales levels or other agreed upon objectives. These bonuses are referred to as “production bonuses” or “marketing development funds.” Additionally, the Company earns revenue from its Population Health platform, including mail-order prescription revenue from SelectRx, and lead generation revenue from InsideResponse. Basis of Presentation —The accompanying unaudited condensed consolidated financial statements include the accounts of SelectQuote, Inc. and its wholly owned subsidiaries: SelectQuote Insurance Services, SelectQuote Auto & Home Insurance Services, LLC (“SQAH”), ChoiceMark Insurance Services, Inc., Tiburon Insurance Services, InsideResponse, LLC, and SelectQuote Ventures, Inc. The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our A nnual Report on Form 10-K for the year ended June 30, 2021, as amended by the Form 10-K/A filed with the SEC on February 14, 2022 (the “2021 Annual Report”) and include all adjustments necessary for the fair presentation of our financial position for the periods presented. Our results for the periods presented in our financial statements are not necessarily indicative of the results to be expected for any subsequent period, including for the year ending June 30, 2022, and therefore should not be relied upon as an indicator of future results. The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements for the year ended June 30, 2021. Certain reclassifications have been made to prior periods to conform with current year presentation. Use of Estimates —The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, and liabilities and disclosure of contingent assets and liabilities. The Company regularly assesses these estimates; however, actual amounts could differ from those estimates. The most significant items involving management’s estimates include estimates of revenue recognition, commissions receivable, the provision for income taxes, share-based compensation, and valuation of intangible assets and goodwill. The impact of changes in estimates is recorded in the period in which they become known. Seasonality —Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year during the Medicare annual enrollment period (“AEP”), which runs from October through December each year, and are allowed to switch plans from an existing plan during the open enrollment period (“OEP”), which runs from January through March each year. As a result, commission revenue for our Senior segment is highest in the second quarter and to a lesser extent, the third quarter during OEP. Most policies sold during AEP are effective as of and renew annually on January 1. Significant Accounting Policies —There have been no material changes to the Company’s significant accounting policies as described in our 2021 Annual Report. Recent Accounting Pronouncements Not Yet Adopted —In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if the acquirer had originated the contracts. Prior to this ASU, an acquirer generally recognizes contract assets acquired and contract liabilities assumed that arose from contracts with customers at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The ASU is to be applied prospectively to business combinations occurring on or after the effective date of the amendment (or if adopted early as of an interim period, as of the beginning of the fiscal year that includes the interim period of early application). The Company will continue to evaluate the impact of this guidance, which will depend on the contract assets and liabilities acquired in future business combinations. Recent Accounting Pronouncements Adopted —In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which simplifies and changes the accounting for certain income tax transactions, among other minor improvements. This standard was effective for the Company on July 1, 2021 and did not have a material impact on the condensed consolidated financial statements and related disclosures. Immaterial Correction of Prior Period Financial Statements —Subsequent to the issuance of the Company’s financial statements as of and for the year ended June 30, 2021, the Company discovered that the provision for first year commission revenue for certain final expense policies offered by one of its insurance carrier partners should have been accrued based on a higher lapse rate. The error in the lapse rate resulted in commission revenue being misstated by $6.1 million and $2.0 million, for the years ended June 30, 2021 and 2020, and $2.4 million for the three months ended September 30, 2021, respectively. Accounts receivable was misstated by $8.1 million and $2.0 million as of June 30, 2021 and 2020, respectively. The impact of the error on net income for the year ended June 30, 2021 was a decrease of $4.8 million. Management has evaluated this misstatement and concluded it was not material to prior periods, individually or in aggregate. However, correcting the cumulative effect of the error in the three and six months ended December 31, 2021 would have had a significant effect on the results of operations. Therefore, the Company is correcting the relevant prior period condensed consolidated financial statements and related footnotes for this error for comparative purposes. The Company will also correct previously reported financial information for such immaterial errors in future filings, as applicable (see “Part II, Item 5. Other Information” below for additional information). The following table reflects the effects of the correction on all affected line items of the Company’s previously reported condensed consolidated statement of comprehensive income (loss) for the three months ended September 30, 2021, which will be corrected in future filings: CORRECTED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (unaudited) Three Months Ended September 30, 2021 (in thousands) As Previously Reported Adjustment As Corrected Commission revenue $ 134,651 $ (2,397) $ 132,254 Total revenue 159,923 (2,397) 157,526 Loss from operations (52,164) (2,397) (54,561) Loss before income tax benefit (60,801) (2,397) (63,198) Income tax benefit (15,436) (609) (16,045) Net loss (45,365) (1,788) (47,153) Net loss per share: Basic (0.28) (0.01) (0.29) Diluted (0.28) (0.01) (0.29) Comprehensive loss $ (45,371) $ (1,788) $ (47,159) The following tables reflect the effects of the correction on all affected line items of the Company’s previously reported condensed consolidated financial statements presented in this Form 10-Q: CORRECTED CONDENSED CONSOLIDATED BALANCE SHEET (unaudited) June 30, 2021 (in thousands) As Previously Reported Adjustment As Corrected Accounts receivable $ 113,375 $ (8,077) $ 105,298 Total current assets 493,435 (8,077) 485,358 Total assets 1,433,872 (8,077) 1,425,795 Deferred income taxes 140,988 (1,748) 139,240 Total liabilities 758,983 (1,748) 757,235 Retained earnings (accumulated deficit) 128,254 (6,329) 121,925 Total shareholders’ equity 674,889 (6,329) 668,560 Total liabilities and shareholders’ equity $ 1,433,872 $ (8,077) $ 1,425,795 CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) Three Months Ended December 31, 2020 Six Months Ended December 31, 2020 (in thousands) As Previously Reported Adjustment As Corrected As Previously Reported Adjustment As Corrected Commission revenue $ 320,974 $ (709) $ 320,265 $ 427,519 $ (2,104) $ 425,415 Total revenue 358,274 (709) 357,565 482,443 (2,104) 480,339 Income (loss) from operations 124,154 (709) 123,445 131,428 (2,104) 129,324 Income (loss) before income tax expense (benefit) 116,956 (709) 116,247 116,689 (2,104) 114,585 Income tax expense (benefit) 26,540 (149) 26,391 25,436 (442) 24,994 Net income (loss) 90,416 (560) 89,856 91,253 (1,662) 89,591 Net income (loss) per share: Basic 0.56 (0.01) 0.55 0.56 (0.01) 0.55 Diluted 0.55 (0.01) 0.54 0.55 (0.01) 0.54 Comprehensive income (loss) $ 90,532 $ (560) $ 89,972 $ 91,112 $ (1,662) $ 89,450 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited) Three Months Ended December 31, 2020 (in thousands) (Accumulated Deficit)/Retained Earnings Total As Previously Reported BALANCES-September 30, 2020 $ (1,955) $ 544,974 Net income 90,416 90,416 BALANCES-December 31, 2020 88,461 634,135 Adjustments BALANCES-September 30, 2020 (2,605) (2,605) Net loss (560) (560) BALANCES-December 31, 2020 (3,165) (3,165) As Corrected BALANCES-September 30, 2020 (4,560) 542,369 Net income 89,856 89,856 BALANCES-December 31, 2020 $ 85,296 $ 630,970 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited) Six Months Ended December 31, 2020 (in thousands) (Accumulated Deficit)/Retained Earnings Total As Previously Reported BALANCES-June 30, 2020 $ (2,792) $ 545,689 Net income 91,253 91,253 BALANCES-December 31, 2020 88,461 634,135 Adjustments BALANCES-June 30, 2020 (1,503) (1,503) Net loss (1,662) (1,662) BALANCES-December 31, 2020 (3,165) (3,165) As Corrected BALANCES-June 30, 2020 (4,295) 544,186 Net income 89,591 89,591 BALANCES-December 31, 2020 $ 85,296 $ 630,970 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (unaudited) Six Months Ended December 31, 2020 (in thousands) As Previously Reported Adjustment As Corrected Net income (loss) $ 91,253 $ (1,662) $ 89,591 Deferred income taxes 25,321 (442) 24,879 Accounts receivable (63,355) 2,104 (61,251) Net cash used in operating activities $ (103,148) $ — $ (103,148)

Acquisitions

Acquisitions	6 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisitions	ACQUISITIONS In accordance with ASC Topic 805, Business Combinations , the Company allocates the purchase price of its acquisitions to the tangible assets, liabilities, and intangible assets acquired based on fair values. Any excess purchase price over those fair values is recorded as goodwill. The fair value assigned to intangible assets acquired is supported by valuations using estimates and assumptions provided by management. Based on the valuation inputs, the Company has recorded assets acquired and liabilities assumed according to the following fair value hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability Lead distribution company —On February 1, 2021, the Company acquired substantially all of the assets of a lead distribution company for an aggregate purchase price of up to $33.5 million (subject to customary adjustments), as set forth in the Asset Purchase Agreement, dated February 1, 2021 (the “Asset Purchase Agreement”). The purchase price is comprised of $30.0 million, of which $24.0 million was paid in cash at the closing of the transaction, with an additional $6.0 million of holdback for indemnification claims, net working capital adjustments, and underperformance. Additionally, the purchase price includes an earnout of up to $3.5 million. The primary purpose of the acquisition was to secure and incorporate the exclusive publisher relationships into the lead generation business of InsideResponse. The Company recorded $0.4 million of acquisition-related costs in general and administrative operating costs and expenses in the condensed consolidated statement of comprehensive income. During calendar year 2021, the lead distribution company did not achieve the minimum earnout target as set forth in the Asset Purchase Agreement; as a result, the earnout payment, which was contingent upon continued employment of certain individuals, will not be paid. However, the remaining holdback was earned in full, as the lead distribution company did not fall below the underperformance thresholds as set forth in the Asset Purchase Agreement. The Company will accrue interest on the remaining holdback of $5.5 million, after the net working capital true-up of $0.5 million, through the 15-month anniversary of the closing date in interest expense, net in the condensed consolidated statement of comprehensive income. Under the terms of the Asset Purchase Agreement, the total consideration for the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 30,000 Net working capital true-up (499) Total Purchase Consideration $ 29,501 At the date of acquisition, the fair value of net tangible assets acquired approximated their carrying value. The non-compete agreements were valued using the income approach, and the customer relationships were valued using the multiple period excess earnings method. As such, all aforementioned intangible assets were valued using Level 3 inputs. Goodwill resulting from the transaction constitutes the excess of the consideration paid over the fair values of the assets acquired and liabilities assumed and primarily represents the benefits of leveraging the exclusive publisher relationships in the business. This acquired goodwill is allocated to Senior (which is also the reporting unit), and is not deductible for tax purposes after adding back acquisition costs and excluding the holdback not yet paid. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Accounts receivable $ 1,301 Total tangible assets acquired 1,301 Non-compete agreements 5 years 1,000 Vendor relationships 9 years 23,700 Goodwill Indefinite 3,500 Total intangible assets acquired 28,200 Net Assets Acquired $ 29,501 The Company will amortize the intangible assets acquired on a straight-line basis over their estimated remaining lives, ranging from five Express Med Pharmaceuticals —On April 30, 2021, the Company acquired 100% of the outstanding shares of Express Med Pharmaceuticals, Inc., now SelectRx, a closed-door, long term care pharmacy provider, for an aggregate purchase price of up to $24.0 million (subject to customary adjustments), as set forth in the Stock Purchase Agreement dated April 30, 2021 (the “Stock Purchase Agreement”). The aggregate purchase price of up to $24.0 million is comprised of $17.5 million in cash paid at the closing of the transaction, an additional $2.5 million of holdback for indemnification claims, if any, and an earnout of up to $4.0 million, if any. The primary purpose of the acquisition was to take advantage of the Company's technology and customer base to facilitate better patient care through coordination of strategic, value-based care partnerships. The Company recorded $0.3 million of acquisition-related costs in general and administrative operating costs and expenses in the condensed consolidated statement of comprehensive income. In addition, as a result of the acquisition, the Company has entered into an operating lease with the former President and Chief Executive Officer of Express Med Pharmaceuticals, now our Executive Vice President of SelectRx. Refer to Note 6 in the condensed consolidated financial statements for further details. The earnout of up to $4.0 million is comprised of two separate provisions. The first provision provides for an earnout of up to $3.0 million and is contingent upon achievement of the following within the first 20 months following the acquisition: facility updates that would allow for processing a minimum of 75,000 active patients, the issuance of pharmacy licenses in all 50 states, and active patients of 15,000 or more. The second provision provides for an earnout of up to $1.0 million and is contingent upon achievement of the following within 36 months following the acquisition: construction of a new facility to accommodate the servicing of additional active patients or 75,000 or more active patients as of the last day of any month prior to the end of the second earnout provision period or as of the end of the second earnout provision period. As the earnout payment is contingent upon continued employment of certain individuals, the Company will recognize the earnout as compensation expense in general and administrative operating costs and expenses in the condensed consolidated statement of comprehensive income in the period in which it is earned. As of December 31, 2021, the Company has not accrued an earnout payment based on performance to date. The $2.5 million of holdback will be due upon the 15-month anniversary of the closing date of the acquisition. Under the terms of the Stock Purchase Agreement, total consideration in the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 20,000 Net working capital true-up (483) Closing cash 20 Total purchase consideration $ 19,537 At the date of acquisition, the fair value of net tangible assets acquired, excluding property and equipment, approximated their carrying value. The property and equipment was valued primarily using the cost and sales comparison approach to value. For the proprietary software acquired, the replacement cost method under the cost approach was used, estimating the cost to rebuild the software. The non-compete agreement was valued using the income approach, and the customer relationships were valued using the multiple period excess earnings method. As such, all aforementioned intangible assets were valued using Level 3 inputs. Goodwill resulting from the transaction constitutes the excess of the consideration paid over the fair values of the assets acquired and liabilities assumed and primarily represents the additional value of the synergies of combining the SelectRx business with the Company's technology and existing customer base. This acquired goodwill is allocated to Senior (which is also the reporting unit), and the Company expects approximately $16.3 million to be deductible for tax purposes after adding back acquisition costs and excluding the holdback not yet paid. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Cash and cash equivalents $ 20 Accounts receivable 613 Other current assets 28 Property and equipment, net 287 Accounts payable (280) Accrued expenses, including compensation and benefits (45) Net tangible assets acquired 623 Proprietary Software 3 years 550 Non-compete agreements 5 years 100 Customer relationships 1 year 200 Goodwill Indefinite 18,064 Total intangible assets acquired 18,914 Net assets acquired $ 19,537 The Company will amortize the intangible assets acquired on a straight-line basis over their estimated remaining lives, ranging from one Simple Meds —On August 31, 2021, SelectRx acquired 100% of the outstanding equity interests of Simple Meds, a full-service pharmaceutical distributor, for an aggregate purchase price of $7.0 million (subject to customary adjustments), as set forth in the Membership Interest Purchase Agreement dated August 31, 2021. The aggregate purchase price of $7.0 million was paid in cash at the closing of the transaction. The primary purpose of the acquisition was to accelerate the expansion of the prescription drug management business by combining the operations and existing infrastructure of Simple Meds into SelectRx. Under the terms of the Membership Interest Purchase Agreement, total consideration in the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 7,000 Net working capital true-up 347 Closing cash 61 Total purchase consideration $ 7,408 At the date of acquisition, the fair value of net tangible assets acquired approximated their carrying value. The customer relationships were valued using the multiple period excess earnings method, and as such, were valued using Level 3 inputs. Goodwill resulting from the transaction constitutes the excess of the consideration paid over the fair values of the assets acquired and liabilities assumed and primarily represents the additional value of the synergies of combining the Simple Meds business with the Company's technology and existing customer base. This acquired goodwill is allocated to Senior (which is also the reporting unit), and the Company expects approximately $5.6 million to be deductible for tax purposes after adding back acquisition costs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Cash and cash equivalents $ 61 Accounts receivable 634 Other current assets 474 Property and equipment, net 415 Accounts payable (259) Net tangible assets acquired 1,325 Customer relationships 1 year 370 Goodwill Indefinite 5,713 Total intangible assets acquired 6,083 Net assets acquired $ 7,408 From the date of acquisition, August 31, 2021, through December 31, 2021, Simple Meds generated $4.0 million of pharmacy prescription revenue.

Property And Equipment_Net

Property And Equipment—Net	6 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property And Equipment—Net	PROPERTY AND EQUIPMENT—NET Property and equipment—net consisted of the following: (in thousands) December 31, 2021 June 30, 2021 Computer hardware $ 25,268 $ 13,351 Machinery and equipment (1) 9,074 2,667 Leasehold improvements 19,536 18,525 Furniture and fixtures 5,229 5,004 Work in progress 5,344 7,220 Total 64,451 46,767 Less accumulated depreciation (21,775) (17,257) Property and equipment—net $ 42,676 $ 29,510 (1) Includes financing lease right-of-use assets. Work in progress as of December 31, 2021 primarily represents computer equipment and leasehold improvements not yet put into service and not yet being depreciated. Work in progress as of June 30, 2021, primarily represents computer equipment and machinery not yet put into service and not yet being depreciated. Depreciation expense for the three months ended December 31, 2021 and 2020, was $2.9 million and $2.0 million, respectively, and $5.1 million and $3.6 million for the six months ended December 31, 2021 and 2020, respectively.

Software_Net

Software—Net	6 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Software—Net	SOFTWARE—NET Software—net consisted of the following: (in thousands) December 31, 2021 June 30, 2021 Software $ 22,322 $ 16,530 Work in progress 3,341 3,826 Total 25,663 20,356 Less accumulated amortization (10,654) (7,745) Software—net $ 15,009 $ 12,611 Work in progress as of December 31, 2021 and June 30, 2021, represents costs incurred for software not yet put into service and are not yet being amortized. For the three months ended December 31, 2021 and 2020, the Company capitalized internal-use software and website development costs of $2.0 million and $1.6 million, respectively, and recorded amortization expense of $1.5 million and $0.8 million, respectively. For the six months ended December 31, 2021 and 2020, the Company capitalized internal-use software and website development costs of $4.5 million and $3.2 million, respectively, and recorded amortization expense of $2.9 million and $1.7 million, respectively.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets — The Company's intangible assets include those acquired as part of the acquisitions listed in the table below (refer to Note 2 to the condensed consolidated financial statements for further details). The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. During each of the three and six months ended December 31, 2021 and 2020, there were no such indicators. Goodwill— The Company recorded as goodwill the excess of the purchase price over the estimated fair values of identifiable assets and liabilities acquired as part of the acquisitions listed in the table below (refer to Note 2 to the condensed consolidated financial statements for further details). The Company performs its annual goodwill impairment assessment as of April 1, or more frequently if it believes that indicators of impairment exist. During each of the three and six months ended December 31, 2021 and 2020 there were no such indicators. Goodwill is assigned to reporting units that are expected to benefit from the synergies of the business combination as of the acquisition date and becomes identified with that reporting unit in its entirety. As such, the reporting unit as a whole supports the recovery of its goodwill. For the following acquisitions, the reporting units to which goodwill has been assigned and the associated reportable segments are as follows: Acquisition Reporting Unit Reportable Segment Auto & Home-controlling interest Auto & Home Auto & Home InsideResponse Senior Senior Lead distribution company Senior Senior Express Med Pharmaceuticals Senior Senior Simple Meds Senior Senior The carrying amounts, accumulated amortization, net carrying value, and weighted average remaining life of our definite-lived amortizable intangible assets as well as our goodwill are presented in the tables below (dollars in thousands, useful life in years): December 31, 2021 June 30, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Useful Life Total intangible assets subject to amortization Customer relationships $ 17,492 $ (4,817) $ 12,675 $ 17,122 $ (3,448) $ 13,674 Trade name 2,680 (893) 1,787 2,680 (625) 2,055 Proprietary software 1,592 (601) 991 1,592 (382) 1,210 Non-compete agreements 1,292 (303) 989 1,292 (163) 1,129 Vendor relationships 23,700 (2,415) 21,285 23,700 (1,098) 22,602 Total intangible assets $ 46,756 $ (9,029) $ 37,727 6.6 $ 46,386 $ (5,716) $ 40,670 7.1 Total indefinite-lived assets Goodwill-Auto & Home $ 5,364 $ 5,364 Goodwill-Senior 68,368 62,655 Total goodwill $ 73,732 $ 68,019 For the three months ended December 31, 2021 and 2020, amortization expense related to intangible assets totaled $1.7 million and $0.8 million, respectively, and $3.3 million and $1.7 million for the six months ended December 31, 2021 and 2020, respectively. Changes in the balance of goodwill for the six months ended December 31, 2021, are as follows (in thousands): Balance, June 30, 2021 $ 68,019 Goodwill from the acquisition of Simple Meds 5,713 Balance, December 31, 2021 $ 73,732 As of December 31, 2021, expected amortization expense in future fiscal periods is as follows (in thousands): Trade Name Proprietary Software Non-compete agreements Vendor Relationships Customer relationships Total Remainder fiscal 2022 $ 268 $ 214 $ 142 $ 1,317 $ 1,415 $ 3,356 2023 536 339 273 2,633 2,385 6,166 2024 536 308 220 2,633 2,319 6,016 2025 447 130 220 2,633 2,316 5,746 2026 — — 134 2,633 2,313 5,080 Thereafter — — — 9,436 1,927 11,363 Total $ 1,787 $ 991 $ 989 $ 21,285 $ 12,675 $ 37,727

Leases

Leases	6 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	LEASESThe majority of the Company’s leases are operating leases related to office space for which the Company recognizes lease expense on a straight-line basis over the respective lease term. The Company leases office facilities in the United States in San Diego, California; Centennial, Colorado; Jacksonville, Florida; Overland Park, Kansas; Wilmington, North Carolina; Des Moines, Iowa; Oakland, California; Indianapolis, Indiana; and Monaca, Pennsylvania (note that SelectRx leases the Monaca facility from an Executive Vice President of SelectRx. The Company expects to incur $3.6 million in total rental payments over the initial ten-year term plus an additional five-year extension option that it is reasonably certain to exercise.) The Company's operating leases have remaining lease terms of less than one year up to fourteen years. Lease Costs —The components of lease costs were as follows periods presented: Three Months Ended December 31, Six Months Ended December 31, (in thousands) 2021 2020 2021 2020 Finance lease costs (1) $ 42 $ 58 $ 84 $ 125 Operating lease costs (2) 2,048 1,952 4,058 3,879 Short-term lease costs 15 58 28 125 Variable lease costs (3) 256 449 469 714 Sublease income (128) (170) (465) (235) Total net lease costs $ 2,233 $ 2,347 $ 4,174 $ 4,608 (1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating costs and expenses and interest expense, net in the condensed consolidated statements of comprehensive income. (2) Recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income. (3) Variable lease costs are not included in the measurement of the lease liability or right-of-use asset as they are not based on an index or rate and primarily represents common area maintenance charges and real estate taxes recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income. Maturities of Lease Liabilities —As of December 31, 2021, remaining maturities of lease liabilities for each of the next five fiscal years and thereafter are as follows: (in thousands) Operating leases Finance leases Total Remainder fiscal 2022 4,552 97 4,649 2023 8,861 27 8,888 2024 9,237 — 9,237 2025 9,254 — 9,254 2026 7,040 — 7,040 2027 5,666 — 5,666 Thereafter 12,884 — 12,884 Total undiscounted lease payments 57,494 124 57,618 Less: interest 15,292 2 15,294 Present value of lease liabilities $ 42,202 $ 122 $ 42,324 As of December 31, 2021, the Company had $3.5 million of undiscounted future payments for operating leases expected to commence between the third quarter of fiscal 2022 and the first quarter of fiscal 2023, with lease terms ranging from seven
Leases	LEASESThe majority of the Company’s leases are operating leases related to office space for which the Company recognizes lease expense on a straight-line basis over the respective lease term. The Company leases office facilities in the United States in San Diego, California; Centennial, Colorado; Jacksonville, Florida; Overland Park, Kansas; Wilmington, North Carolina; Des Moines, Iowa; Oakland, California; Indianapolis, Indiana; and Monaca, Pennsylvania (note that SelectRx leases the Monaca facility from an Executive Vice President of SelectRx. The Company expects to incur $3.6 million in total rental payments over the initial ten-year term plus an additional five-year extension option that it is reasonably certain to exercise.) The Company's operating leases have remaining lease terms of less than one year up to fourteen years. Lease Costs —The components of lease costs were as follows periods presented: Three Months Ended December 31, Six Months Ended December 31, (in thousands) 2021 2020 2021 2020 Finance lease costs (1) $ 42 $ 58 $ 84 $ 125 Operating lease costs (2) 2,048 1,952 4,058 3,879 Short-term lease costs 15 58 28 125 Variable lease costs (3) 256 449 469 714 Sublease income (128) (170) (465) (235) Total net lease costs $ 2,233 $ 2,347 $ 4,174 $ 4,608 (1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating costs and expenses and interest expense, net in the condensed consolidated statements of comprehensive income. (2) Recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income. (3) Variable lease costs are not included in the measurement of the lease liability or right-of-use asset as they are not based on an index or rate and primarily represents common area maintenance charges and real estate taxes recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income. Maturities of Lease Liabilities —As of December 31, 2021, remaining maturities of lease liabilities for each of the next five fiscal years and thereafter are as follows: (in thousands) Operating leases Finance leases Total Remainder fiscal 2022 4,552 97 4,649 2023 8,861 27 8,888 2024 9,237 — 9,237 2025 9,254 — 9,254 2026 7,040 — 7,040 2027 5,666 — 5,666 Thereafter 12,884 — 12,884 Total undiscounted lease payments 57,494 124 57,618 Less: interest 15,292 2 15,294 Present value of lease liabilities $ 42,202 $ 122 $ 42,324 As of December 31, 2021, the Company had $3.5 million of undiscounted future payments for operating leases expected to commence between the third quarter of fiscal 2022 and the first quarter of fiscal 2023, with lease terms ranging from seven

Debt

Debt	6 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	DEBTDebt consisted of the following: (in thousands) December 31, 2021 June 30, 2021 Term Loans $ 471,912 $ 471,912 DDTL Facility 245,000 — Unamortized debt issuance costs (3,469) (4,081) Unamortized debt discount (5,924) (6,428) Total debt 707,519 461,403 Less current portion of long-term debt: (7,169) (2,360) Long-term debt $ 700,350 $ 459,043 On November 5, 2019, the Company entered into a credit agreement with UMB Bank N.A. (“UMB”) as a lender and revolving agent and Morgan Stanley Capital Administrators, Inc. as a lender and the administrative agent for a syndicate of lenders party to the agreement. On February 24, 2021, November 2, 2021, and December 23, 2021, the Company entered into amendments to the credit agreement ( individually, the “First Amendment”, “Second Amendment”, and “Third Amendment” , together with the original credit agreement and any subsequent amendments, the “Senior Secured Credit Facility” ) with certain of its existing lenders and new lenders. The First Amendment provided for an additional $231.0 million in term loans (together with the initial $425.0 million, the “Term Loans”) and added a $145.0 million se nior secured delayed draw term loan facility (the "DDTL Facility") . The Second Amendment provided for additional commitments of $25.0 million, in addition to the initial $75.0 million, for the s ecured revolving loan facility (the “Revolving Credit Facility”) and an additional $200.0 million under the DDTL Facility. The Third Amendment provided for additional commitments of $35.0 million under the Revolving Credit Facility. After giving effect to the amendments, in aggregate, as of December 31, 2021, the Senior Secured Credit Facility provides for (1) an aggregate principal amount of up to $135.0 million under the Revolving Credit Facility (2) Term Loans in an aggregate principal amount of $656.0 million, of which $471.9 million is outstanding as of December 31, 2021, and (3) a $345.0 million DDTL Facility, of which the Company borrowed $245.0 million on December 22, 2021. As of February 7, 2022, the available borrowing capacities under the Revolving Credit Facility and DDTL Facility were $135.0 million and $100.0 million, respectively. In accordance with ASC 470-50-40 “ Debt Modification and Extinguishments, ” the Second and Third Amendments were accounted for as debt modifications, and the $3.0 million original issue discount paid to the two lenders of the DDTL Facility was capitalized and is being amortized on a straight-line basis over the remaining life of the agreement through interest expense. Additionally, the Company paid $1.2 million in costs as part of the transaction that were included in general and administrative expense in the condensed consolidated statements of comprehensive income. As a result of the Third Amendment, the Company incurred $0.3 million of costs related to the new commitments, which costs were capitalized and are being amortized on a straight-line basis over the remaining life of the agreement through interest expense. The Revolving Credit Facility accrues interest on amounts drawn at a rate per annum equal to either (a) LIBOR plus 4.0% or (b) a base rate plus 3.0%, at the Company’s option, and the Company pays an unused commitment fee of 0.15% in respect of the unutilized commitments under the Revolving Credit Facility. The Term Loans and any loans under the DDTL Facility bear interest on the outstanding principal amount thereof at a rate per annum equal to either (a) LIBOR (subject to a floor of 0.75%) plus 5.00% or (b) a base rate plus 4.00%, at the Company’s option, and the Company pays a ticking fee based on the average daily balance of the unused amount of the aggregate DDTL Facility commitments during the preceding fiscal quarter, multiplied by 1% per annum. The Senior Secured Credit Facility has a maturity date of November 5, 2024, with the Term Loans being mandatorily repayable beginning March 31, 2022, in equal quarterly installments in an aggregate annual amount equal to 1% of the original principal amount of the Term Loans, with the remaining balance payable on the maturity date. The DDTL Facility is also mandatorily repayable beginning March 31, 2022, in equal quarterly installments equal to 0.25% of all DDTL facility loans that have been outstanding for a full fiscal quarter prior to each such repayment date, with the remaining balance payable on the maturity date. The remaining $100.0 million of the DDTL Facility may be drawn from time to time, subject to certain conditions, until January 15, 2023. The Senior Secured Credit Facility contains customary affirmative and negative covenants and events of default and a financial covenant requiring the Company and certain of its subsidiaries to maintain a minimum asset coverage ratio. As of December 31, 2021, the Company was in compliance with all of the required covenants. The obligations of the Company are guaranteed by certain of the Company’s subsidiaries and secured by a security interest in all assets of the Company, subject to certain exceptions. The Company has incurred a total of $27.1 million in debt issuance costs and debt discounts related to the Senior Secured Credit Facility, of which $22.9 million was capitalized and is being amortized on a straight-line basis over the remaining life of the Senior Secured Credit Facility. Total amortization was $2.1 million and $0.8 million for the three months ended December 31, 2021 and 2020, respectively, and $3.0 million and $1.6 million for the six months ended December 31, 2021 and 2020, respectively, which was included in interest expense, net in the Company’s condensed consolidated statements of comprehensive income. The Company uses derivative financial instruments to hedge against its exposure to fluctuations in interest rates associated with the Term Loans. As of December 31, 2021, the Company had an outstanding receive-variable, pay-fixed interest rate swap on the notional amount of $325.0 million of the Company’s total outstanding Term Loans balance with a fixed rate of 5.00% plus 1.03% (the “Amended Interest Rate Swap”), which terminates on November 5, 2024. The Company classifies its Amended Interest Rate Swap as a Level 2 on the fair value hierarchy as the majority of the inputs used to value it primarily includes other than quoted prices that are observable, and it uses standard calculations and models that use readily observable market data as their basis. As of December 31, 2021, the Company estimates that $0.6 million will be reclassified into interest expense during the next twelve months.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Lease Obligations —Refer to Note 6 to the condensed consolidated financial statements for commitments related to our operating leases. Legal Contingencies and Obligations —From time to time, the Company is subject to legal proceedings and claims in the ordinary course of business. The Company currently is not aware of any legal proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition, operating results, or cash flows. On August 17, 2021, a putative securities class action lawsuit was filed against the Company and two of its executive officers in the U.S. District Court for the Southern District of New York. The complaint, captioned Hartel v. SelectQuote, Inc., et al. , Case No. 1:21-cv-06903, asserts securities fraud claims on behalf of a putative class of plaintiffs who purchased or otherwise acquired shares of the Company’s common stock between February 8, 2021 and May 11, 2021 (the “Hartel Relevant Period”). Specifically, the complaint alleges the defendants violated Sections 10(b) and 20(a) and Rule 10b-5 of the Exchange Act by making materially false and misleading statements and failing to disclose material adverse facts about the Company’s business, operations, and prospects, allegedly causing the Company’s common stock to trade at artificially inflated prices during the Hartel Relevant Period. The plaintiffs seek unspecified damages and reimbursement of attorneys’ fees and certain other costs. On October 7, 2021, a putative securities class action lawsuit was filed in the U.S. District Court for the Southern District of New York against the Company, two of its executive officers, and six current or former members of the Company’s Board of Directors, along with the underwriters of the Company’s initial public offering of common stock (the “Offering”). The complaint, captioned West Palm Beach Police Pension Fund v. SelectQuote, Inc., et al., Case No. 1:21-cv-08279, asserts claims for securities law violations on behalf of a putative class of plaintiffs who purchased shares of the Company’s common stock (i) in or traceable to the Offering or (ii) between May 20, 2020 and August 25, 2021 (the “WPB Relevant Period”). Specifically, the complaint alleges the defendants violated Sections 10(b) and 20(a) and Rule 10b-5 of the Exchange Act by making materially false and misleading statements and failing to disclose material adverse facts about the Company’s financial well-being and prospects, allegedly causing the Company’s common stock to trade at artificially inflated prices during the WPB Relevant Period. The complaint also alleges the defendants violated Sections 11, 12(a)(2), and 15 of the Securities Act by making misstatements and omissions of material facts in connection with the Offering, allegedly causing a decline in the value of the Company’s common stock. The plaintiffs seek unspecified damages, rescission, and reimbursement of attorneys’ fees and certain other costs. The Company believes the allegations in the complaints are without merit and intends to defend the cases vigorously. Accordingly, we currently believe that these matters will not have a material adverse effect on any of our results of operations, financial condition or liquidity. However, depending on how the matters progress, they could be costly to defend and could divert the attention of management and other resources from operations. The Company has not concluded that a loss is probable and, therefore, has not accrued a liability related to these matters.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Shareholders' Equity	SHAREHOLDERS' EQUITY Common Stock —As of December 31, 2021, the Company has reserved the following authorized, but unissued, shares of common stock: Employee Stock Purchase Plan (“ESPP”) 1,253,575 Stock awards outstanding under 2020 Plan 3,603,818 Stock awards available for grant under 2020 Plan 10,721,627 Options outstanding under 2003 Plan 1,717,264 Total 17,296,284 Share-Based Compensation Plans The Company has awards outstanding from two share-based compensation plans: the 2003 Stock Incentive Plan (the “2003 Stock Plan”) and the 2020 Omnibus Incentive Plan (the “2020 Stock Plan” and, collectively with the 2003 Stock Plan, the “Stock Plans”). However, no further awards will be made under the 2003 Stock Plan. The 2020 Stock Plan provides for the grant of incentive stock options (“ISO's”), nonstatutory stock options (“NSO's”), stock appreciation rights, restricted stock awards, restricted stock unit awards (“RSU's”), performance-based restricted stock units (“PSU's”), and other forms of equity compensation (collectively, “stock awards”). All awards (other than ISOs, which may be granted only to current employees of the Company) may be granted to employees, non-employee directors, and consultants of the Company and its subsidiaries and affiliates. The number of shares of common stock available for issuance as of December 31, 2021, pursuant to future awards under the Company's 2020 Stock Plan is 10,721,627. The number of shares of the Company's common stock reserved under the 2020 Stock Plan is subject to an annual increase on the first day of each fiscal year, beginning on July 1, 2021, equal to 3% of the total outstanding shares of common stock as of the last day of the immediately preceding fiscal year. The maximum number of shares of common stock that may be issued upon the exercise of ISO's will be 4,000,000. The shares of common stock covered by any award (including any award granted pursuant to the 2003 Stock Plan) that is forfeited, terminated, expired, or lapsed without being exercised or settled for cash will again become available for issuance under the 2020 Stock Plan. With respect to any award, if the exercise price and/or tax withholding obligations are satisfied by delivering shares to the Company (by actual delivery or attestation), or if the exercise price and/or tax withholding obligations are satisfied by withholding shares otherwise issuable pursuant to the award, the share reserve shall nonetheless be reduced by the gross number of shares subject to the award. The Company accounts for its share-based compensation awards in accordance with ASC 718, Compensation—Stock Compensation (“ASC 718”) which requires all share-based compensation to be recognized in the income statement based on fair value and applies to all awards granted, modified, canceled, or repurchased after the effective date. Total share-based compensation for stock awards included in general and administrative expense in the condensed consolidated statements of comprehensive income was as follows for the periods presented: Three Months Ended December 31, Six Months Ended December 31, (in thousands) 2021 2020 2021 2020 Share-based compensation related to: Equity classified stock options $ 884 $ 455 $ 1,624 $ 818 Equity classified RSU's 1,127 545 2,080 960 Equity classified PSU's (305) 194 87 322 Total $ 1,706 $ 1,194 $ 3,791 $ 2,100 Stock Options — The stock options outstanding under the 2003 Stock Plan vest as to one-third after the vesting commencement date and as to 1/24 of the remaining shares subject to the stock option monthly thereafter, subject to the award recipient’s continued employment through the applicable vesting date. Upon a termination of employment for any reason other than for “Cause” (as defined in the 2003 Stock Plan), any unvested and outstanding stock options would generally be forfeited for no consideration, and any vested and outstanding stock options would remain exercisable for 90 days following the date of termination (and, in the case of a termination of employment due to death or disability, for 12 months following the date of termination). Stock options expire 10 years from the date of grant. The terms for ISO's and NSO's awarded in the 2020 Stock Plan are the same as in the 2003 Stock Plan with the exception that the options generally shall vest and become exercisable in four equal installments on each of the first four anniversaries of the grant date, subject to the award recipient’s continued employment through the applicable vesting date. Stock options are granted with an exercise price that is no less than 100% of the fair market value of the underlying shares on the date of the grant. The fair value of each option (for purposes of calculation of share-based compensation expense) is estimated using the Black-Scholes-Merton option pricing model that uses assumptions determined as of the date of the grant. Use of this option pricing model requires the input of subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of the Company's common stock price over the expected term (“volatility”), the number of options that will ultimately not complete their vesting requirements (“assumed forfeitures”), the risk-free interest rate that reflects the interest rate at grant date on zero-coupon United States governmental bonds that have a remaining life similar to the expected term (“risk-free interest rate”), and the dividend yield assumption which is based on the Company's dividend payment history and management's expectations of future dividend payments (“dividend yield”). Changes in the subjective assumptions can materially affect the estimate of the fair value of share-based compensation and, consequently, the related amount recognized in the condensed consolidated statements of comprehensive income. The Company used the following weighted-average assumptions for the stock options granted during the periods presented below: Six Months Ended December 31, 2021 2020 Volatility 30.2% 25.0% Risk-free interest rate 0.9% 0.4% Dividend yield —% —% Assumed forfeitures —% —% Expected term (in years) 6.25 6.24 Weighted-average fair value (per share) $5.52 $4.86 The following table summarizes stock option activity under the Stock Plans for the six months ended December 31, 2021: Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (in Thousands) Outstanding—June 30, 2021 3,398,513 $ 8.60 Options granted 1,254,089 17.61 Options exercised (339,670) 3.81 Options forfeited/expired/cancelled (34,068) 17.12 Outstanding—December 31, 2021 4,278,864 $ 11.54 6.78 $ 13,904 Vested and exercisable—December 31, 2021 2,009,390 $ 3.89 4.16 $ 13,759 As of December 31, 2021, there was $10.2 million in unrecognized compensation cost related to unvested stock options granted, which is expected to be recognized over a weighted-average period of 3.10 years. The Company received cash of $0.1 million and $0.1 million in connection with stock options exercised during the three months ended December 31, 2021 and 2020, respectively, and $2.3 million and $0.4 million in connection with stock options exercised, net of cashless exercises, during the six months ended December 31, 2021 and 2020, respectively. Restricted Stock — The following table summarizes restricted stock unit activity under the 2020 Stock Plan for the six months ended December 31, 2021: Number of Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested as of June 30, 2021 356,285 $ 19.12 Granted 453,679 16.78 Vested (82,689) 19.61 Cancelled (14,058) 17.84 Unvested as of December 31, 2021 713,217 $ 17.61 As of December 31, 2021, there was $10.7 million of unrecognized compensation cost related to unvested restricted stock units granted, which is expected to be recognized over a weighted-average period of 2.96 years. Performance Stock — The following table summarizes performance stock unit activity under the 2020 Stock Plan for the six months ended December 31, 2021: Number of Performance Stock Units Weighted-Average Grant Date Fair Value Unvested as of June 30, 2021 (1) 132,921 $ 17.97 Granted (1) 196,080 17.80 Vested — — Performance adjustment (2) (164,500) Cancelled — — Unvested as of December 31, 2021 164,501 $ 17.87 (1) Reflects PSU’s at 100% achievement of predefined financial performance targets. If performance metrics are met, PSU’s will vest, at the end of a three-year performance period. The number of shares that could be earned for the fiscal year 2021 tranche will range from 0% to 150% of the target, and the number of shares that could be earned for the fiscal year 2022 tranche will range from 0% to 200% of the target. (2) Represents adjustments to previously granted PSU’s to reflect changes in estimates of future financial performance against targets. As of December 31, 2021, there was $2.1 million of unrecognized compensation cost related to unvested performance stock units granted, which is expected to be recognized over a weighted-average period of 2.31 years. ESPP — The purpose of the ESPP is to provide the Company's eligible employees with an opportunity to purchase shares of its common stock through accumulated payroll deductions at 95% of the fair market value on the exercise date, but no less than the lesser of 85% of the fair market value of a share of common stock on the date the offering period commences or 85% of the fair market value of the common stock on the exercise date. For the six months ended December 31, 2021, the Company issued 89,985 shares to its employees and as of December 31, 2021, there are 1,253,575 shares reserved for future issuance under the plan. The Company recorded share-based compensation expense of $0.2 million and $0.1 million with respect to the ESPP for the three months ended December 31, 2021 and 2020, respectively, and recorded share-based compensation expense of $0.3 million and $0.1 million with respect to the ESPP for the six months ended December 31, 2021 and 2020, respectively.

Revenues from Contracts with Cu

Revenues from Contracts with Customers	6 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenues from Contracts with Customers	REVENUES FROM CONTRACTS WITH CUSTOMERS Disaggregation of Revenue from Contracts with Customers —The disaggregation of revenue by segment and product is depicted for the periods presented below, and is consistent with how the Company evaluates its financial performance: Three Months Ended December 31, Six Months Ended December 31, (in thousands) 2021 2020 2021 2020 Senior: Commission revenue: Medicare advantage $ 99,262 $ 263,975 $ 179,345 $ 312,705 Medicare supplement 2,332 12,743 3,936 20,735 Prescription drug plan 732 1,102 1,001 1,717 Dental, vision, and health 4,920 5,647 8,136 8,370 Other commission revenue 1,954 743 2,854 1,203 Total commission revenue 109,200 284,210 195,272 344,730 Production bonus and other revenue 48,767 31,300 69,015 43,979 Total Senior revenue 157,967 315,510 264,287 388,709 Life: Commission revenue: Term 16,126 20,028 32,372 39,772 Final expense 10,886 9,816 35,473 26,274 Total commission revenue 27,012 29,844 67,845 66,046 Production bonus and other revenue 5,768 5,822 12,366 11,048 Total Life revenue 32,780 35,666 80,211 77,094 Auto & Home: Total commission revenue 5,657 6,491 12,649 15,104 Production bonus and other revenue 478 750 955 1,675 Total Auto & Home revenue 6,135 7,241 13,604 16,779 Eliminations: Total commission revenue (1,168) (280) (2,810) (465) Production bonus and other revenue (733) (572) (2,784) (1,778) Total Elimination revenue (1,901) (852) (5,594) (2,243) Total commission revenue 140,701 320,265 272,956 425,415 Total production bonus and other revenue 54,280 37,300 79,552 54,924 Total revenue $ 194,981 $ 357,565 $ 352,508 $ 480,339 Contract Balances —After a policy is sold, the Company has no material additional or recurring obligations to the policyholder or the insurance carrier. As such, there are no contract liabilities recorded in the condensed consolidated balance sheets. During the six months ended December 31, 2020, there was no activity in the contract asset balances other than the movement over time between long-term and short-term commissions receivable and accounts receivable as the policy is renewed, as shown on the balance sheet. A roll forward of commissions receivable (current and long term) is shown below for the six months ended December 31, 2021: (in thousands) Balance as of June 30, 2021 $ 845,897 Commission revenue from revenue recognized 212,976 Net commission revenue adjustment from change in estimate (149,174) Amounts recognized as accounts receivable (23,894) Balance as of December 31, 2021 $ 885,805 The $149.2 million adjustment from change in estimate includes adjustments from the Company’s reassessment of each of its cohorts’ transaction prices. $145.0 million of the total adjustment is due to the increase in actual lapse rates for Senior MA policies during calendar year 2021 and overall lower persistency from early data received for the January 2022 renewals. Therefore, it was determined that a downward adjustment to Senior MA revenue was probable, and commission revenue was reduced during the three months ended December 31, 2021. Approximately 62%, 28%, and 8% of the adjustment from the change in estimate were from approved policies sold in fiscal years 2021, 2020, and 2019, respectively. Production Bonuses and Other —During the six months ended December 31, 2021, the Company received advance payments of marketing development funds, which will be amortized over the course of the appropriate fiscal year based on policies sold. As of December 31, 2021, there was an unamortized balance remaining of $2.3 million of fiscal year 2022 marketing development funds recorded in other current liabilities in the condensed consolidated balance sheet.

Income Taxes

Income Taxes	6 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES For the three months ended December 31, 2021 and 2020, we recognized income tax benefit of $46.5 million and income tax expense of $26.4 million, respectively, representing effective tax rates of 25.4% and 22.7%, respectively. The differences from our federal statutory tax rate to the effective tax rate for the three months ended December 31, 2021, were primarily related to state income taxes. The differences from our federal statutory tax rate to the effective tax rate for the three months ended December 31, 2020, were primarily related to state income taxes, partially offset by state tax credits such as the Kansas High Performance Incentive Program (“HPIP”) and discrete items for the period related to the exercise of non-qualified stock options. For the six months ended December 31, 2021 and 2020, we recognized income tax benefit of $62.6 million and income tax expense of $25.0 million, respectively, representing effective tax rates of 25.4% and 21.8%, respectively. The differences from our federal statutory tax rate to the effective tax rate for the six months ended December 31, 2021, were primarily related to state income taxes. The differences from our federal statutory tax rate to the effective tax rate for the six months ended December 31, 2020, were primarily related to state income taxes, partially offset by state tax credits such as HPIP and discrete items for the period related to the exercise of non-qualified stock options. Assessing the realizability of the Company’s deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. The Company forecasts taxable income by considering all available positive and negative evidence, including historical data and future plans and estimates. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. The Company continues to recognize its deferred tax assets as of December 31, 2021, as it believes it is more likely than not that the net deferred tax assets will be realized. The Company recognizes a significant deferred tax liability due to the difference in the timing of revenue recognition for financial statement and tax purposes. For financial statement purposes, revenue is recognized when a policy is sold, while revenue recognition for tax purposes occurs when future renewal commission payments are received. This deferred tax liability is a source of income that can be used to support the realizability of the Company’s deferred tax assets. As such, the Company does not believe a valuation

Net Income (Loss) Per Share

Net Income (Loss) Per Share	6 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	NET INCOME (LOSS) PER SHARE The Company calculates net income (loss) per share as defined by ASC Topic 260, “ Earnings per Share” . Basic net income (loss) per share (“Basic EPS”) is computed by dividing net income (loss) attributable to common shareholders by the weighted-average common stock outstanding during the respective period. Diluted net income (loss) per share (“Diluted EPS”) is computed by dividing net income (loss) attributable to common and common equivalent shareholders by the total of the weighted-average common stock outstanding and common equivalent shares outstanding during the respective period. For the purpose of calculating the Company’s Diluted EPS, common equivalent shares outstanding include common shares issuable upon the exercise of outstanding employee stock options, unvested RSU's, PSU’s assuming the performance conditions are satisfied as of the end of the reporting period, and common shares issuable upon the conclusion of each ESPP offering period. The number of common equivalent shares outstanding has been determined in accordance with the treasury stock method for employee stock options, RSU's, PSU’s, and common stock issuable pursuant to the ESPP to the extent they are dilutive. Under the treasury stock method, the exercise price paid by the option holder and future share-based compensation expense that the Company has not yet recognized are assumed to be used to repurchase shares. The following table sets forth the computation of net income (loss) per share for the periods presented: Three Months Ended December 31, Six Months Ended December 31, (in thousands, except per share amounts) 2021 2020 2021 2020 Basic: Numerator: Net income (loss) $ (137,008) $ 89,856 $ (184,161) $ 89,591 Net income (loss) attributable to common shareholders (137,008) 89,856 (184,161) 89,591 Denominator: Weighted-average common stock outstanding 163,966 162,645 163,829 162,546 Net income (loss) per share—basic: $ (0.84) $ 0.55 $ (1.12) $ 0.55 Diluted: Numerator: Net income (loss) attributable to common shareholders $ (137,008) $ 89,856 $ (184,161) $ 89,591 Net income (loss) attributable to common and common equivalent shareholders (137,008) 89,856 (184,161) 89,591 Denominator: Weighted-average common stock outstanding 163,966 162,645 163,829 162,546 Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP (1) — 2,918 — 2,831 Total common and common equivalent shares outstanding 163,966 165,563 163,829 165,377 Net income (loss) per share—diluted: $ (0.84) $ 0.54 $ (1.12) $ 0.54 (1) Excluded from the computation of net income (loss) per share-diluted for the three and six months ended December 31, 2021, because the effect would have been anti-dilutive. The weighted average potential shares of common stock that were excluded from the calculation of net income (loss) per share-diluted for the periods presented because including them would have been anti-dilutive are as follows for the periods presented: Three Months Ended December 31, Six Months Ended December 31, (in thousands) 2021 2020 2021 2020 Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP 5,133 — 4,908 — Shares subject to outstanding PSU's (1) 165 — 247 — Total 5,298 — 5,155 — (1) The weighted-average number of shares excluded from the computation of net income (loss) per share-diluted because the performance conditions associated with these awards were not met.

Segment Information

Segment Information	6 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company’s reportable segments have been determined in accordance with ASC 280, Segment Reporting (“ASC 280”). The Company currently has three reportable segments: i) Senior, ii) Life, and iii) Auto & Home. Senior primarily sells senior Medicare-related health insurance products and also includes Population Health and InsideResponse. Life primarily sells term life and final expense products, and Auto & Home primarily sells individual automobile and homeowners’ insurance. In addition, the Company accounts for non-operating activity, share-based compensation expense, certain intersegment eliminations, and the costs of providing corporate and other administrative services in its administrative division, Corporate & Eliminations. These services are not directly identifiable with the Company’s reportable segments and are shown in the tables below to reconcile the reportable segments to the condensed consolidated financial statements. The Company has not aggregated any operating segments together to represent a reportable segment. The Company reports segment information based on how its chief operating decision maker (“CODM”) regularly reviews its operating results, allocates resources, and makes decisions regarding business operations. The performance measures of the segments include total revenue and Adjusted EBITDA because management believes that such information is the most relevant in evaluating the results of the respective segments relative to other entities that operate in the same industries. Costs of revenue, marketing and advertising, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is calculated as total revenue for the applicable segment less direct and allocated costs of revenue, marketing and advertising, technical development, and general and administrative operating costs and expenses, excluding depreciation and amortization expense; gain or loss on disposal of property, equipment, and software; share-based compensation expense; restructuring expenses; and non-recurring expenses such as severance payments and transaction costs. Our CODM does not separately evaluate assets by segment; therefore, assets by segment are not presented. The following table presents information about the reportable segments for the three months ended December 31, 2021: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 157,967 $ 32,780 $ 6,135 $ (1,901) $ 194,981 Operating expenses (306,602) (30,930) (4,700) (15,979) (1) (358,211) Other expenses, net — — — (51) (51) Adjusted EBITDA $ (148,635) $ 1,850 $ 1,435 $ (17,931) (163,281) Share-based compensation expense (1,894) Non-recurring expenses (2) (1,602) Depreciation and amortization (6,175) Loss on disposal of property, equipment, and software (5) Interest expense, net (10,587) Income tax benefit 46,536 Net loss $ (137,008) (1) Operating expenses in the Corp & Elims division primarily include $11.2 million in salaries and benefits for certain general, administrative, and IT related departments, and $4.3 million in professional services fees. (2) These expenses primarily consist of debt issuance costs incurred for the Second Amendment. The following table presents information about the reportable segments for the three months ended December 31, 2020: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 315,510 $ 35,666 $ 7,241 $ (852) $ 357,565 Operating expenses (180,955) (29,961) (5,091) (12,746) (1) (228,753) Other expenses, net — — — (21) (21) Adjusted EBITDA $ 134,555 $ 5,705 $ 2,150 $ (13,619) 128,791 Share-based compensation expense (1,336) Non-recurring expenses (2) (362) Fair value adjustments to contingent earnout obligations (395) Depreciation and amortization (3,590) Loss on disposal of property, equipment, and software (79) Interest expense, net (6,782) Income tax expense (26,391) Net income $ 89,856 (1) Operating expenses in the Corp & Elims division primarily include $8.4 million in salaries and benefits for certain general, administrative, and IT related departments and $3.3 million in professional services fees. (2) These expenses primarily consist of non-recurring compensation to a former executive and expenses related to business continuity in response to the COVID-19 pandemic. The following table presents information about the reportable segments for the six months ended December 31, 2021: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 264,287 $ 80,211 $ 13,604 $ (5,594) $ 352,508 Operating expenses (445,893) (76,058) (10,796) (29,330) (1) (562,077) Other expenses, net — — — (153) (153) Adjusted EBITDA $ (181,606) $ 4,153 $ 2,808 $ (35,077) (209,722) Share-based compensation expense (4,109) Non-recurring expenses (2) (2,155) Depreciation and amortization (11,278) Loss on disposal of property, equipment, and software (355) Interest expense, net (19,122) Income tax benefit 62,580 Net loss $ (184,161) (1) Operating expenses in the Corp & Elims division primarily include $21.6 million in salaries and benefits for certain general, administrative, and IT related departments, and $9.0 million in professional services fees. (2) These expenses primarily consist of costs incurred for the Second Amendment and costs related to the acquisitions of Express Med Pharmaceuticals and Simple Meds. The following table presents information about the reportable segments for the six months ended December 31, 2020: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 388,709 $ 77,094 $ 16,779 $ (2,243) $ 480,339 Operating expenses (245,252) (62,307) (11,012) (22,264) (1) (340,835) Other expenses, net — — — (43) (43) Adjusted EBITDA $ 143,457 $ 14,787 $ 5,767 $ (24,550) 139,461 Share-based compensation expense (2,259) Non-recurring expenses (2) (822) Fair value adjustments to contingent earnout obligations (1,153) Depreciation and amortization (6,937) Loss on disposal of property, equipment, and software (162) Interest expense, net (13,543) Income tax expense (24,994) Net income $ 89,591 (1) Operating expenses in the Corp & Elims division primarily include $15.0 million in salaries and benefits for certain general, administrative, and IT related departments and $6.3 million in professional services fees. (2) These expenses primarily consist of non-recurring compensation to a former executive, non-restructuring severance expenses, costs related to our IPO, and expenses related to business continuity in response to the COVID-19 pandemic. Revenues from each of the reportable segments are earned from transactions in the United States and follow the same accounting policies used for the Company’s condensed consolidated financial statements. All of the Company’s long-lived assets are located in the United States. For the three months ended December 31, 2021, three insurance carrier customers from Senior accounted for 24%, 15%, and 11% of total revenue, respectively. For the three months ended December 31, 2020, three insurance carrier customers from Senior, accounted for 30%, 22%,

Summary of Business and Signi_2

Summary of Business and Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Description of Business	Description of Business —SelectQuote, Inc. (together with its subsidiaries, the “Company” or “SelectQuote”) contracts with insurance carriers to sell senior health, life, and auto and home insurance policies by telephone to individuals throughout the United States through the use of multi-channel marketing and advertising campaigns. The Company obtains leads from, among other sources, InsideResponse, a wholly-owned subsidiary that provides sales leads to the consumer insurance industry. The Company also coordinates various healthcare-related services through its Population Health platform, which includes SelectRx, a closed-door, long-term care pharmacy that offers pharmacy services, including essential prescription medications, OTC medications, customized medication packaging, medication therapy management, and other consultative services under the Patient Centered Pharmacy Home (PCPH) model. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products, and along with Population Health and InsideResponse, is referred to as “Senior”. SelectQuote’s Life division (“Life”) sells term life, final expense, and other ancillary products, and SelectQuote’s Auto & Home division (“Auto & Home”) primarily sells non-commercial auto and home property and casualty insurance products. SelectQuote’s licensed insurance agents provide comparative rates from a variety of insurance carriers relying on our technology distribution channel with a combination of proprietary and commercially available software to perform its quote service and sell insurance policies on behalf of the insurance carriers. The Company primarily earns revenue in the form of commission payments from the insurance carriers. Commission payments are received both when the initial policy is sold (“first year”) and when the underlying policyholder renews their policy in subsequent years (“renewal”). The Company also receives certain volume-based bonuses from some carriers on first-year policies sold based on attaining various predetermined target sales levels or other agreed upon objectives. These bonuses are referred to as “production bonuses” or “marketing development funds.” Additionally, the Company earns revenue from its Population Health platform, including mail-order prescription revenue from SelectRx, and lead generation revenue from InsideResponse.
Basis of Presentation	Basis of Presentation —The accompanying unaudited condensed consolidated financial statements include the accounts of SelectQuote, Inc. and its wholly owned subsidiaries: SelectQuote Insurance Services, SelectQuote Auto & Home Insurance Services, LLC (“SQAH”), ChoiceMark Insurance Services, Inc., Tiburon Insurance Services, InsideResponse, LLC, and SelectQuote Ventures, Inc. The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our A nnual Report on Form 10-K for the year ended June 30, 2021, as amended by the Form 10-K/A filed with the SEC on February 14, 2022 (the “2021 Annual Report”) and include all adjustments necessary for the fair presentation of our financial position for the periods presented. Our results for the periods presented in our financial statements are not necessarily indicative of the results to be expected for any subsequent period, including for the year ending June 30, 2022, and therefore should not be relied upon as an indicator of future results. The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements for the year ended June 30, 2021. Certain reclassifications have been made to prior periods to conform with current year presentation.
Use of Estimates	Use of Estimates —The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, and liabilities and disclosure of contingent assets and liabilities. The Company regularly assesses these estimates; however, actual amounts could differ from those estimates. The most significant items involving management’s estimates include estimates of
Seasonality	Seasonality —Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year during the Medicare annual enrollment period (“AEP”), which runs from October through December each year, and are allowed to switch plans from an existing plan during the open enrollment period (“OEP”), which runs from January through March each year. As a result, commission revenue for our Senior segment is highest in the second quarter and to a lesser extent, the third quarter during OEP. Most policies sold during AEP are effective as of and renew annually on January 1.
Recent Accounting Pronouncements Not Yet Adopted and Recent Accounting Pronouncements Adopted	Recent Accounting Pronouncements Not Yet Adopted —In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if the acquirer had originated the contracts. Prior to this ASU, an acquirer generally recognizes contract assets acquired and contract liabilities assumed that arose from contracts with customers at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The ASU is to be applied prospectively to business combinations occurring on or after the effective date of the amendment (or if adopted early as of an interim period, as of the beginning of the fiscal year that includes the interim period of early application). The Company will continue to evaluate the impact of this guidance, which will depend on the contract assets and liabilities acquired in future business combinations. Recent Accounting Pronouncements Adopted —In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which simplifies and changes the accounting for certain income tax transactions, among other minor improvements. This standard was effective for the Company on July 1, 2021 and did not have a material impact on the condensed consolidated financial statements and related disclosures.

Summary of Business and Signi_3

Summary of Business and Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The following table reflects the effects of the correction on all affected line items of the Company’s previously reported condensed consolidated statement of comprehensive income (loss) for the three months ended September 30, 2021, which will be corrected in future filings: CORRECTED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (unaudited) Three Months Ended September 30, 2021 (in thousands) As Previously Reported Adjustment As Corrected Commission revenue $ 134,651 $ (2,397) $ 132,254 Total revenue 159,923 (2,397) 157,526 Loss from operations (52,164) (2,397) (54,561) Loss before income tax benefit (60,801) (2,397) (63,198) Income tax benefit (15,436) (609) (16,045) Net loss (45,365) (1,788) (47,153) Net loss per share: Basic (0.28) (0.01) (0.29) Diluted (0.28) (0.01) (0.29) Comprehensive loss $ (45,371) $ (1,788) $ (47,159) The following tables reflect the effects of the correction on all affected line items of the Company’s previously reported condensed consolidated financial statements presented in this Form 10-Q: CORRECTED CONDENSED CONSOLIDATED BALANCE SHEET (unaudited) June 30, 2021 (in thousands) As Previously Reported Adjustment As Corrected Accounts receivable $ 113,375 $ (8,077) $ 105,298 Total current assets 493,435 (8,077) 485,358 Total assets 1,433,872 (8,077) 1,425,795 Deferred income taxes 140,988 (1,748) 139,240 Total liabilities 758,983 (1,748) 757,235 Retained earnings (accumulated deficit) 128,254 (6,329) 121,925 Total shareholders’ equity 674,889 (6,329) 668,560 Total liabilities and shareholders’ equity $ 1,433,872 $ (8,077) $ 1,425,795 CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) Three Months Ended December 31, 2020 Six Months Ended December 31, 2020 (in thousands) As Previously Reported Adjustment As Corrected As Previously Reported Adjustment As Corrected Commission revenue $ 320,974 $ (709) $ 320,265 $ 427,519 $ (2,104) $ 425,415 Total revenue 358,274 (709) 357,565 482,443 (2,104) 480,339 Income (loss) from operations 124,154 (709) 123,445 131,428 (2,104) 129,324 Income (loss) before income tax expense (benefit) 116,956 (709) 116,247 116,689 (2,104) 114,585 Income tax expense (benefit) 26,540 (149) 26,391 25,436 (442) 24,994 Net income (loss) 90,416 (560) 89,856 91,253 (1,662) 89,591 Net income (loss) per share: Basic 0.56 (0.01) 0.55 0.56 (0.01) 0.55 Diluted 0.55 (0.01) 0.54 0.55 (0.01) 0.54 Comprehensive income (loss) $ 90,532 $ (560) $ 89,972 $ 91,112 $ (1,662) $ 89,450 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited) Three Months Ended December 31, 2020 (in thousands) (Accumulated Deficit)/Retained Earnings Total As Previously Reported BALANCES-September 30, 2020 $ (1,955) $ 544,974 Net income 90,416 90,416 BALANCES-December 31, 2020 88,461 634,135 Adjustments BALANCES-September 30, 2020 (2,605) (2,605) Net loss (560) (560) BALANCES-December 31, 2020 (3,165) (3,165) As Corrected BALANCES-September 30, 2020 (4,560) 542,369 Net income 89,856 89,856 BALANCES-December 31, 2020 $ 85,296 $ 630,970 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited) Six Months Ended December 31, 2020 (in thousands) (Accumulated Deficit)/Retained Earnings Total As Previously Reported BALANCES-June 30, 2020 $ (2,792) $ 545,689 Net income 91,253 91,253 BALANCES-December 31, 2020 88,461 634,135 Adjustments BALANCES-June 30, 2020 (1,503) (1,503) Net loss (1,662) (1,662) BALANCES-December 31, 2020 (3,165) (3,165) As Corrected BALANCES-June 30, 2020 (4,295) 544,186 Net income 89,591 89,591 BALANCES-December 31, 2020 $ 85,296 $ 630,970 CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (unaudited) Six Months Ended December 31, 2020 (in thousands) As Previously Reported Adjustment As Corrected Net income (loss) $ 91,253 $ (1,662) $ 89,591 Deferred income taxes 25,321 (442) 24,879 Accounts receivable (63,355) 2,104 (61,251) Net cash used in operating activities $ (103,148) $ — $ (103,148)

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Fair Value Hierarchy	The fair value assigned to intangible assets acquired is supported by valuations using estimates and assumptions provided by management. Based on the valuation inputs, the Company has recorded assets acquired and liabilities assumed according to the following fair value hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability
Summary of Total Consideration of the Acquisition	Under the terms of the Asset Purchase Agreement, the total consideration for the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 30,000 Net working capital true-up (499) Total Purchase Consideration $ 29,501 Under the terms of the Stock Purchase Agreement, total consideration in the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 20,000 Net working capital true-up (483) Closing cash 20 Total purchase consideration $ 19,537 Under the terms of the Membership Interest Purchase Agreement, total consideration in the acquisition consisted of the following as of the acquisition date (in thousands): Base purchase price $ 7,000 Net working capital true-up 347 Closing cash 61 Total purchase consideration $ 7,408
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Accounts receivable $ 1,301 Total tangible assets acquired 1,301 Non-compete agreements 5 years 1,000 Vendor relationships 9 years 23,700 Goodwill Indefinite 3,500 Total intangible assets acquired 28,200 Net Assets Acquired $ 29,501 The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Cash and cash equivalents $ 20 Accounts receivable 613 Other current assets 28 Property and equipment, net 287 Accounts payable (280) Accrued expenses, including compensation and benefits (45) Net tangible assets acquired 623 Proprietary Software 3 years 550 Non-compete agreements 5 years 100 Customer relationships 1 year 200 Goodwill Indefinite 18,064 Total intangible assets acquired 18,914 Net assets acquired $ 19,537 The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Description Estimated Life Amount Cash and cash equivalents $ 61 Accounts receivable 634 Other current assets 474 Property and equipment, net 415 Accounts payable (259) Net tangible assets acquired 1,325 Customer relationships 1 year 370 Goodwill Indefinite 5,713 Total intangible assets acquired 6,083 Net assets acquired $ 7,408

Property And Equipment_Net (Tab

Property And Equipment—Net (Tables)	6 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment—net consisted of the following: (in thousands) December 31, 2021 June 30, 2021 Computer hardware $ 25,268 $ 13,351 Machinery and equipment (1) 9,074 2,667 Leasehold improvements 19,536 18,525 Furniture and fixtures 5,229 5,004 Work in progress 5,344 7,220 Total 64,451 46,767 Less accumulated depreciation (21,775) (17,257) Property and equipment—net $ 42,676 $ 29,510 (1) Includes financing lease right-of-use assets.

Software_Net (Tables)

Software—Net (Tables)	6 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Capitalized Software	Software—net consisted of the following: (in thousands) December 31, 2021 June 30, 2021 Software $ 22,322 $ 16,530 Work in progress 3,341 3,826 Total 25,663 20,356 Less accumulated amortization (10,654) (7,745) Software—net $ 15,009 $ 12,611

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Acquired Goodwill	For the following acquisitions, the reporting units to which goodwill has been assigned and the associated reportable segments are as follows: Acquisition Reporting Unit Reportable Segment Auto & Home-controlling interest Auto & Home Auto & Home InsideResponse Senior Senior Lead distribution company Senior Senior Express Med Pharmaceuticals Senior Senior Simple Meds Senior Senior
Schedule of Intangible Assets and Goodwill	The carrying amounts, accumulated amortization, net carrying value, and weighted average remaining life of our definite-lived amortizable intangible assets as well as our goodwill are presented in the tables below (dollars in thousands, useful life in years): December 31, 2021 June 30, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Useful Life Total intangible assets subject to amortization Customer relationships $ 17,492 $ (4,817) $ 12,675 $ 17,122 $ (3,448) $ 13,674 Trade name 2,680 (893) 1,787 2,680 (625) 2,055 Proprietary software 1,592 (601) 991 1,592 (382) 1,210 Non-compete agreements 1,292 (303) 989 1,292 (163) 1,129 Vendor relationships 23,700 (2,415) 21,285 23,700 (1,098) 22,602 Total intangible assets $ 46,756 $ (9,029) $ 37,727 6.6 $ 46,386 $ (5,716) $ 40,670 7.1 Total indefinite-lived assets Goodwill-Auto & Home $ 5,364 $ 5,364 Goodwill-Senior 68,368 62,655 Total goodwill $ 73,732 $ 68,019
Schedule of Goodwill	Changes in the balance of goodwill for the six months ended December 31, 2021, are as follows (in thousands): Balance, June 30, 2021 $ 68,019 Goodwill from the acquisition of Simple Meds 5,713 Balance, December 31, 2021 $ 73,732
Schedule of Future Amortization Expense	As of December 31, 2021, expected amortization expense in future fiscal periods is as follows (in thousands): Trade Name Proprietary Software Non-compete agreements Vendor Relationships Customer relationships Total Remainder fiscal 2022 $ 268 $ 214 $ 142 $ 1,317 $ 1,415 $ 3,356 2023 536 339 273 2,633 2,385 6,166 2024 536 308 220 2,633 2,319 6,016 2025 447 130 220 2,633 2,316 5,746 2026 — — 134 2,633 2,313 5,080 Thereafter — — — 9,436 1,927 11,363 Total $ 1,787 $ 991 $ 989 $ 21,285 $ 12,675 $ 37,727

Leases (Tables)

Leases (Tables)	6 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of Lease Costs and Supplemental Information	The components of lease costs were as follows periods presented: Three Months Ended December 31, Six Months Ended December 31, (in thousands) 2021 2020 2021 2020 Finance lease costs (1) $ 42 $ 58 $ 84 $ 125 Operating lease costs (2) 2,048 1,952 4,058 3,879 Short-term lease costs 15 58 28 125 Variable lease costs (3) 256 449 469 714 Sublease income (128) (170) (465) (235) Total net lease costs $ 2,233 $ 2,347 $ 4,174 $ 4,608 (1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating costs and expenses and interest expense, net in the condensed consolidated statements of comprehensive income. (2) Recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income. (3) Variable lease costs are not included in the measurement of the lease liability or right-of-use asset as they are not based on an index or rate and primarily represents common area maintenance charges and real estate taxes recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income.
Schedule of Maturity of Operating Lease Liabilities	Maturities of Lease Liabilities —As of December 31, 2021, remaining maturities of lease liabilities for each of the next five fiscal years and thereafter are as follows: (in thousands) Operating leases Finance leases Total Remainder fiscal 2022 4,552 97 4,649 2023 8,861 27 8,888 2024 9,237 — 9,237 2025 9,254 — 9,254 2026 7,040 — 7,040 2027 5,666 — 5,666 Thereafter 12,884 — 12,884 Total undiscounted lease payments 57,494 124 57,618 Less: interest 15,292 2 15,294 Present value of lease liabilities $ 42,202 $ 122 $ 42,324
Schedule of Maturity of Finance Lease Liabilities	Maturities of Lease Liabilities —As of December 31, 2021, remaining maturities of lease liabilities for each of the next five fiscal years and thereafter are as follows: (in thousands) Operating leases Finance leases Total Remainder fiscal 2022 4,552 97 4,649 2023 8,861 27 8,888 2024 9,237 — 9,237 2025 9,254 — 9,254 2026 7,040 — 7,040 2027 5,666 — 5,666 Thereafter 12,884 — 12,884 Total undiscounted lease payments 57,494 124 57,618 Less: interest 15,292 2 15,294 Present value of lease liabilities $ 42,202 $ 122 $ 42,324

Debt (Tables)

Debt (Tables)	6 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Debt consisted of the following: (in thousands) December 31, 2021 June 30, 2021 Term Loans $ 471,912 $ 471,912 DDTL Facility 245,000 — Unamortized debt issuance costs (3,469) (4,081) Unamortized debt discount (5,924) (6,428) Total debt 707,519 461,403 Less current portion of long-term debt: (7,169) (2,360) Long-term debt $ 700,350 $ 459,043

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Stock by Class	As of December 31, 2021, the Company has reserved the following authorized, but unissued, shares of common stock: Employee Stock Purchase Plan (“ESPP”) 1,253,575 Stock awards outstanding under 2020 Plan 3,603,818 Stock awards available for grant under 2020 Plan 10,721,627 Options outstanding under 2003 Plan 1,717,264 Total 17,296,284
Schedule of Share-Based Compensation Activity	Total share-based compensation for stock awards included in general and administrative expense in the condensed consolidated statements of comprehensive income was as follows for the periods presented: Three Months Ended December 31, Six Months Ended December 31, (in thousands) 2021 2020 2021 2020 Share-based compensation related to: Equity classified stock options $ 884 $ 455 $ 1,624 $ 818 Equity classified RSU's 1,127 545 2,080 960 Equity classified PSU's (305) 194 87 322 Total $ 1,706 $ 1,194 $ 3,791 $ 2,100
Schedule of Stock Options, Valuation Assumptions	The Company used the following weighted-average assumptions for the stock options granted during the periods presented below: Six Months Ended December 31, 2021 2020 Volatility 30.2% 25.0% Risk-free interest rate 0.9% 0.4% Dividend yield —% —% Assumed forfeitures —% —% Expected term (in years) 6.25 6.24 Weighted-average fair value (per share) $5.52 $4.86
Schedule of Stock Options Roll Forward	The following table summarizes stock option activity under the Stock Plans for the six months ended December 31, 2021: Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (in Thousands) Outstanding—June 30, 2021 3,398,513 $ 8.60 Options granted 1,254,089 17.61 Options exercised (339,670) 3.81 Options forfeited/expired/cancelled (34,068) 17.12 Outstanding—December 31, 2021 4,278,864 $ 11.54 6.78 $ 13,904 Vested and exercisable—December 31, 2021 2,009,390 $ 3.89 4.16 $ 13,759
Schedule of Restricted Stock Unit Activity	The following table summarizes restricted stock unit activity under the 2020 Stock Plan for the six months ended December 31, 2021: Number of Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested as of June 30, 2021 356,285 $ 19.12 Granted 453,679 16.78 Vested (82,689) 19.61 Cancelled (14,058) 17.84 Unvested as of December 31, 2021 713,217 $ 17.61
Schedule of Performance Stock Activity	The following table summarizes performance stock unit activity under the 2020 Stock Plan for the six months ended December 31, 2021: Number of Performance Stock Units Weighted-Average Grant Date Fair Value Unvested as of June 30, 2021 (1) 132,921 $ 17.97 Granted (1) 196,080 17.80 Vested — — Performance adjustment (2) (164,500) Cancelled — — Unvested as of December 31, 2021 164,501 $ 17.87 (1) Reflects PSU’s at 100% achievement of predefined financial performance targets. If performance metrics are met, PSU’s will vest, at the end of a three-year performance period. The number of shares that could be earned for the fiscal year 2021 tranche will range from 0% to 150% of the target, and the number of shares that could be earned for the fiscal year 2022 tranche will range from 0% to 200% of the target. (2) Represents adjustments to previously granted PSU’s to reflect changes in estimates of future financial performance against targets.

Revenue from Contracts with Cus

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The disaggregation of revenue by segment and product is depicted for the periods presented below, and is consistent with how the Company evaluates its financial performance: Three Months Ended December 31, Six Months Ended December 31, (in thousands) 2021 2020 2021 2020 Senior: Commission revenue: Medicare advantage $ 99,262 $ 263,975 $ 179,345 $ 312,705 Medicare supplement 2,332 12,743 3,936 20,735 Prescription drug plan 732 1,102 1,001 1,717 Dental, vision, and health 4,920 5,647 8,136 8,370 Other commission revenue 1,954 743 2,854 1,203 Total commission revenue 109,200 284,210 195,272 344,730 Production bonus and other revenue 48,767 31,300 69,015 43,979 Total Senior revenue 157,967 315,510 264,287 388,709 Life: Commission revenue: Term 16,126 20,028 32,372 39,772 Final expense 10,886 9,816 35,473 26,274 Total commission revenue 27,012 29,844 67,845 66,046 Production bonus and other revenue 5,768 5,822 12,366 11,048 Total Life revenue 32,780 35,666 80,211 77,094 Auto & Home: Total commission revenue 5,657 6,491 12,649 15,104 Production bonus and other revenue 478 750 955 1,675 Total Auto & Home revenue 6,135 7,241 13,604 16,779 Eliminations: Total commission revenue (1,168) (280) (2,810) (465) Production bonus and other revenue (733) (572) (2,784) (1,778) Total Elimination revenue (1,901) (852) (5,594) (2,243) Total commission revenue 140,701 320,265 272,956 425,415 Total production bonus and other revenue 54,280 37,300 79,552 54,924 Total revenue $ 194,981 $ 357,565 $ 352,508 $ 480,339
Schedule of Activity in Commissions Receivable	A roll forward of commissions receivable (current and long term) is shown below for the six months ended December 31, 2021: (in thousands) Balance as of June 30, 2021 $ 845,897 Commission revenue from revenue recognized 212,976 Net commission revenue adjustment from change in estimate (149,174) Amounts recognized as accounts receivable (23,894) Balance as of December 31, 2021 $ 885,805

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	6 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of net income (loss) per share for the periods presented: Three Months Ended December 31, Six Months Ended December 31, (in thousands, except per share amounts) 2021 2020 2021 2020 Basic: Numerator: Net income (loss) $ (137,008) $ 89,856 $ (184,161) $ 89,591 Net income (loss) attributable to common shareholders (137,008) 89,856 (184,161) 89,591 Denominator: Weighted-average common stock outstanding 163,966 162,645 163,829 162,546 Net income (loss) per share—basic: $ (0.84) $ 0.55 $ (1.12) $ 0.55 Diluted: Numerator: Net income (loss) attributable to common shareholders $ (137,008) $ 89,856 $ (184,161) $ 89,591 Net income (loss) attributable to common and common equivalent shareholders (137,008) 89,856 (184,161) 89,591 Denominator: Weighted-average common stock outstanding 163,966 162,645 163,829 162,546 Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP (1) — 2,918 — 2,831 Total common and common equivalent shares outstanding 163,966 165,563 163,829 165,377 Net income (loss) per share—diluted: $ (0.84) $ 0.54 $ (1.12) $ 0.54 (1) Excluded from the computation of net income (loss) per share-diluted for the three and six months ended December 31, 2021, because the effect would have been anti-dilutive.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The weighted average potential shares of common stock that were excluded from the calculation of net income (loss) per share-diluted for the periods presented because including them would have been anti-dilutive are as follows for the periods presented: Three Months Ended December 31, Six Months Ended December 31, (in thousands) 2021 2020 2021 2020 Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP 5,133 — 4,908 — Shares subject to outstanding PSU's (1) 165 — 247 — Total 5,298 — 5,155 — (1) The weighted-average number of shares excluded from the computation of net income (loss) per share-diluted because the performance conditions associated with these awards were not met.

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table presents information about the reportable segments for the three months ended December 31, 2021: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 157,967 $ 32,780 $ 6,135 $ (1,901) $ 194,981 Operating expenses (306,602) (30,930) (4,700) (15,979) (1) (358,211) Other expenses, net — — — (51) (51) Adjusted EBITDA $ (148,635) $ 1,850 $ 1,435 $ (17,931) (163,281) Share-based compensation expense (1,894) Non-recurring expenses (2) (1,602) Depreciation and amortization (6,175) Loss on disposal of property, equipment, and software (5) Interest expense, net (10,587) Income tax benefit 46,536 Net loss $ (137,008) (1) Operating expenses in the Corp & Elims division primarily include $11.2 million in salaries and benefits for certain general, administrative, and IT related departments, and $4.3 million in professional services fees. (2) These expenses primarily consist of debt issuance costs incurred for the Second Amendment. The following table presents information about the reportable segments for the three months ended December 31, 2020: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 315,510 $ 35,666 $ 7,241 $ (852) $ 357,565 Operating expenses (180,955) (29,961) (5,091) (12,746) (1) (228,753) Other expenses, net — — — (21) (21) Adjusted EBITDA $ 134,555 $ 5,705 $ 2,150 $ (13,619) 128,791 Share-based compensation expense (1,336) Non-recurring expenses (2) (362) Fair value adjustments to contingent earnout obligations (395) Depreciation and amortization (3,590) Loss on disposal of property, equipment, and software (79) Interest expense, net (6,782) Income tax expense (26,391) Net income $ 89,856 (1) Operating expenses in the Corp & Elims division primarily include $8.4 million in salaries and benefits for certain general, administrative, and IT related departments and $3.3 million in professional services fees. (2) These expenses primarily consist of non-recurring compensation to a former executive and expenses related to business continuity in response to the COVID-19 pandemic. The following table presents information about the reportable segments for the six months ended December 31, 2021: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 264,287 $ 80,211 $ 13,604 $ (5,594) $ 352,508 Operating expenses (445,893) (76,058) (10,796) (29,330) (1) (562,077) Other expenses, net — — — (153) (153) Adjusted EBITDA $ (181,606) $ 4,153 $ 2,808 $ (35,077) (209,722) Share-based compensation expense (4,109) Non-recurring expenses (2) (2,155) Depreciation and amortization (11,278) Loss on disposal of property, equipment, and software (355) Interest expense, net (19,122) Income tax benefit 62,580 Net loss $ (184,161) (1) Operating expenses in the Corp & Elims division primarily include $21.6 million in salaries and benefits for certain general, administrative, and IT related departments, and $9.0 million in professional services fees. (2) These expenses primarily consist of costs incurred for the Second Amendment and costs related to the acquisitions of Express Med Pharmaceuticals and Simple Meds. The following table presents information about the reportable segments for the six months ended December 31, 2020: (in thousands) Senior Life Auto & Home Corp & Elims Consolidated Revenue $ 388,709 $ 77,094 $ 16,779 $ (2,243) $ 480,339 Operating expenses (245,252) (62,307) (11,012) (22,264) (1) (340,835) Other expenses, net — — — (43) (43) Adjusted EBITDA $ 143,457 $ 14,787 $ 5,767 $ (24,550) 139,461 Share-based compensation expense (2,259) Non-recurring expenses (2) (822) Fair value adjustments to contingent earnout obligations (1,153) Depreciation and amortization (6,937) Loss on disposal of property, equipment, and software (162) Interest expense, net (13,543) Income tax expense (24,994) Net income $ 89,591 (1) Operating expenses in the Corp & Elims division primarily include $15.0 million in salaries and benefits for certain general, administrative, and IT related departments and $6.3 million in professional services fees. (2) These expenses primarily consist of non-recurring compensation to a former executive, non-restructuring severance expenses, costs related to our IPO, and expenses related to business continuity in response to the COVID-19 pandemic.

Summary of Business and Signi_4

Summary of Business and Significant Accounting Policies - Revised Balance Sheet and Statements of Comprehensive Income (Loss) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Sep. 30, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue	$ 194,981	$ 157,526	$ 357,565	$ 352,508	$ 480,339
Income (loss) from operations	(172,906)	(54,561)	123,445	(227,466)	129,324
Income (loss) before income tax expense (benefit)	(183,544)	(63,198)	116,247	(246,741)	114,585
Income tax expense (benefit)	(46,536)	(16,045)	26,391	(62,580)	24,994
Net income (loss)	$ (137,008)	$ (47,153)	$ 89,856	$ (184,161)	$ 89,591
Basic (in dollars per share)	$ (0.84)	$ (0.29)	$ 0.55	$ (1.12)	$ 0.55
Diluted (in dollars per share)	$ (0.84)	$ (0.29)	$ 0.54	$ (1.12)	$ 0.54
COMPREHENSIVE INCOME	$ (135,233)	$ (47,159)	$ 89,972	$ (182,392)	$ 89,450
Accounts receivable	149,399			149,399		$ 105,298
Total current assets	555,556			555,556		485,358
Total assets	1,444,833			1,444,833		1,425,795
Deferred income taxes	76,942			76,942		139,240
Total liabilities	952,429			952,429		757,235
Retained earnings (accumulated deficit)	(62,236)			(62,236)		121,925
Total shareholders’ equity	492,404	625,668	630,970	492,404	630,970	668,560	$ 544,186	$ 542,369
Total liabilities and shareholders’ equity	1,444,833			1,444,833		1,425,795
Life
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue	32,780		35,666	80,211	77,094
Final expense | Life
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue	10,886		9,816	35,473	26,274
Commission
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue	140,701	132,254	320,265	272,956	425,415
Commission | Life
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue	$ 27,012		29,844	$ 67,845	66,046
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue		159,923	358,274		482,443
Income (loss) from operations		(52,164)	124,154		131,428
Income (loss) before income tax expense (benefit)		(60,801)	116,956		116,689
Income tax expense (benefit)		(15,436)	26,540		25,436
Net income (loss)		$ (45,365)	$ 90,416		$ 91,253
Basic (in dollars per share)		$ (0.28)	$ 0.56		$ 0.56
Diluted (in dollars per share)		$ (0.28)	$ 0.55		$ 0.55
COMPREHENSIVE INCOME		$ (45,371)	$ 90,532		$ 91,112
Accounts receivable						113,375
Total current assets						493,435
Total assets						1,433,872
Deferred income taxes						140,988
Total liabilities						758,983
Retained earnings (accumulated deficit)						128,254
Total shareholders’ equity			634,135		634,135	674,889	545,689	544,974
Total liabilities and shareholders’ equity						1,433,872
As Previously Reported | Commission
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue		134,651	320,974		427,519
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue		(2,397)	(709)		(2,104)
Income (loss) from operations		(2,397)	(709)		(2,104)
Income (loss) before income tax expense (benefit)		(2,397)	(709)		(2,104)
Income tax expense (benefit)		(609)	(149)		(442)
Net income (loss)		$ (1,788)	$ (560)		$ (1,662)	(4,800)
Basic (in dollars per share)		$ (0.01)	$ (0.01)		$ (0.01)
Diluted (in dollars per share)		$ (0.01)	$ (0.01)		$ (0.01)
COMPREHENSIVE INCOME		$ (1,788)	$ (560)		$ (1,662)
Accounts receivable						(8,077)	(2,000)
Total current assets						(8,077)
Total assets						(8,077)
Deferred income taxes						(1,748)
Total liabilities						(1,748)
Retained earnings (accumulated deficit)						(6,329)
Total shareholders’ equity			(3,165)		(3,165)	(6,329)	(1,503)	$ (2,605)
Total liabilities and shareholders’ equity						(8,077)
Adjustment | Commission
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenue		$ (2,397)	$ (709)		$ (2,104)	$ (6,100)	$ (2,000)

Summary of Business and Signi_5

Summary of Business and Significant Accounting Policies - Revised Equity Statements and Note 10 (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 625,668	$ 668,560	$ 542,369	$ 668,560	$ 544,186	$ 544,186
Net income (loss)	(137,008)	(47,153)	89,856	(184,161)	89,591
Ending balance	492,404	625,668	630,970	492,404	630,970	668,560	$ 544,186
Deferred income taxes				(62,940)	24,879
Accounts receivable				(43,429)	(61,251)
Net cash used in operating activities				(305,741)	(103,148)
Total revenue	194,981	157,526	357,565	352,508	480,339
Life
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total revenue	32,780		35,666	80,211	77,094
Final expense | Life
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total revenue	10,886		9,816	35,473	26,274
Commission
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total revenue	140,701	132,254	320,265	272,956	425,415
Commission | Life
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total revenue	27,012		29,844	67,845	66,046
As Previously Reported
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		674,889	544,974	674,889	545,689	545,689
Net income (loss)		(45,365)	90,416		91,253
Ending balance			634,135		634,135	674,889	545,689
Deferred income taxes					25,321
Accounts receivable					(63,355)
Net cash used in operating activities					(103,148)
Total revenue		159,923	358,274		482,443
As Previously Reported | Commission
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total revenue		134,651	320,974		427,519
Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		(6,329)	(2,605)	(6,329)	(1,503)	(1,503)
Net income (loss)		(1,788)	(560)		(1,662)	(4,800)
Ending balance			(3,165)		(3,165)	(6,329)	(1,503)
Deferred income taxes					(442)
Accounts receivable					2,104
Net cash used in operating activities					0
Total revenue		(2,397)	(709)		(2,104)
Adjustment | Commission
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total revenue		(2,397)	(709)		(2,104)	(6,100)	(2,000)
Retained Earnings/(Accumulated Deficit)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	74,772	121,925	(4,560)	121,925	(4,295)	(4,295)
Net income (loss)	(137,008)		89,856	(184,161)	89,591
Ending balance	$ (62,236)	$ 74,772	85,296	$ (62,236)	85,296	121,925	(4,295)
Retained Earnings/(Accumulated Deficit) | As Previously Reported
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance			(1,955)		(2,792)	(2,792)
Net income (loss)			90,416		91,253
Ending balance			88,461		88,461		(2,792)
Retained Earnings/(Accumulated Deficit) | Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance			(2,605)		(1,503)	$ (1,503)
Net income (loss)			(560)		(1,662)
Ending balance			$ (3,165)		$ (3,165)		$ (1,503)

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) $ in Thousands	Aug. 31, 2021USD ($)	Apr. 30, 2021USD ($)provisionpatientsegment	Feb. 01, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Business Acquisition [Line Items]
Fair value adjustments to contingent earnout obligations				$ 395		$ 0	$ 1,153
Weighted-Average Remaining Useful Life						6 years 7 months 6 days	7 years 1 month 6 days
Lead Distribution Company
Business Acquisition [Line Items]
Purchase consideration, net			$ 33,500
Base purchase price			30,000
Payments to acquire businesses, gross			24,000
Holdback for indemnification claims			6,000
Contingent consideration, liability			3,500
Fair value adjustments to contingent earnout obligations			400
Remaining holdback for indemnification claims			5,500
Net working capital true-up			$ 499
Net working capital true-up time period			15 months
Aggregate purchase price			$ 29,501
Lead Distribution Company | Minimum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life			5 years
Lead Distribution Company | Maximum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life			9 years
Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Base purchase price		$ 20,000
Holdback for indemnification claims		2,500
Contingent consideration, liability		4,000
Fair value adjustments to contingent earnout obligations		300
Net working capital true-up		$ 483
Net working capital true-up time period		15 months
Percentage of voting interests acquired		100.00%
Aggregate purchase price		$ 24,000
Cash acquired from acquisition		$ 17,500
Number of provisions | provision		2
Consideration arrangements provision one		$ 3,000
Contingent consideration provision one period		20 months
Contingent consideration provision one, minimum number of patients processed | segment		75,000
Contingent consideration provision two		$ 1,000
Contingent consideration, number of active patients | patient		15,000
Contingent consideration provision two period		36 months
Capacity of new facility | segment		75,000
Business acquisition, goodwill, expected tax deductible amount					$ 16,300	$ 16,300
Express Med Pharmaceutical Inc | Minimum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life		1 year
Express Med Pharmaceutical Inc | Maximum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life		5 years
Simple Meds
Business Acquisition [Line Items]
Base purchase price	$ 7,000
Payments to acquire businesses, gross	7,000
Net working capital true-up	(347)
Aggregate purchase price	$ 7,408
Business acquisition, goodwill, expected tax deductible amount					5,600	$ 5,600
Revenue generated from business acquisition					$ 4,000

Acquisitions - Consideration (D

Acquisitions - Consideration (Details) - USD ($) $ in Thousands	Aug. 31, 2021	Apr. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Total purchase consideration			$ 6,927	$ (121)
Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Base purchase price		$ 20,000
Net working capital true-up		(483)
Closing cash		20
Total purchase consideration		19,537
Total purchase consideration		$ 24,000
Simple Meds
Business Acquisition [Line Items]
Base purchase price	$ 7,000
Net working capital true-up	347
Closing cash	61
Total purchase consideration	$ 7,408

Acquisitions - Estimated Fair V

Acquisitions - Estimated Fair Value Of Assets Acquired And Liabilities Assumed (Details) - USD ($) $ in Thousands	Aug. 31, 2021	Apr. 30, 2021	Feb. 01, 2021	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Business Acquisition [Line Items]
Goodwill				$ 73,732		$ 68,019
Weighted-Average Remaining Useful Life				6 years 7 months 6 days	7 years 1 month 6 days
Lead Distribution Company
Business Acquisition [Line Items]
Accounts receivable			$ 1,301
Net tangible assets acquired			1,301
Goodwill			3,500
Total intangible assets acquired			28,200
Net assets acquired			$ 29,501
Lead Distribution Company | Minimum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life			5 years
Lead Distribution Company | Maximum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life			9 years
Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Cash and cash equivalents		$ 20
Accounts receivable		613
Other current assets		28
Property and equipment, net		287
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable		(280)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities		(45)
Net tangible assets acquired		623
Goodwill		18,064
Total intangible assets acquired		18,914
Net assets acquired		$ 19,537
Express Med Pharmaceutical Inc | Minimum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life		1 year
Express Med Pharmaceutical Inc | Maximum
Business Acquisition [Line Items]
Weighted-Average Remaining Useful Life		5 years
Simple Meds
Business Acquisition [Line Items]
Cash and cash equivalents	$ 61
Accounts receivable	634
Other current assets	474
Property and equipment, net	415
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	(259)
Net tangible assets acquired	1,325
Goodwill	5,713
Total intangible assets acquired	6,083
Net assets acquired	7,408
Proprietary Software | Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Intangible assets		$ 550
Weighted-Average Remaining Useful Life		3 years
Non-compete agreements | Lead Distribution Company
Business Acquisition [Line Items]
Intangible assets			$ 1,000
Weighted-Average Remaining Useful Life			5 years
Non-compete agreements | Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Intangible assets		$ 100
Weighted-Average Remaining Useful Life		5 years
Customer relationships | Express Med Pharmaceutical Inc
Business Acquisition [Line Items]
Intangible assets		$ 200
Weighted-Average Remaining Useful Life		1 year
Customer relationships | Simple Meds
Business Acquisition [Line Items]
Intangible assets	$ 370
Weighted-Average Remaining Useful Life	1 year
Vendor relationships | Lead Distribution Company
Business Acquisition [Line Items]
Intangible assets			$ 23,700
Weighted-Average Remaining Useful Life			9 years

Property And Equipment_Net - Su

Property And Equipment—Net - Summary (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Total	$ 64,451	$ 46,767
Less accumulated depreciation	(21,775)	(17,257)
PROPERTY AND EQUIPMENT—Net	42,676	29,510
Computer hardware
Property, Plant and Equipment [Line Items]
Property and equipment, gross	25,268	13,351
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total	9,074	2,667
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19,536	18,525
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,229	5,004
Work in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 5,344	$ 7,220

Property And Equipment_Net - Na

Property And Equipment—Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 2.9	$ 2	$ 5.1	$ 3.6

Software_Net - Summary (Details

Software—Net - Summary (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Software, gross	$ 25,663	$ 20,356
Less accumulated amortization	(10,654)	(7,745)
SOFTWARE—Net	15,009	12,611
Proprietary Software
Finite-Lived Intangible Assets [Line Items]
Software, gross	22,322	16,530
Work in progress
Finite-Lived Intangible Assets [Line Items]
Software, gross	$ 3,341	$ 3,826

Software_Net - Narrative (Detai

Software—Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Capitalized software costs in the period	$ 2	$ 1.6	$ 4.5	$ 3.2
Capitalized software amortization	$ (1.5)	$ (0.8)	$ (2.9)	$ (1.7)

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, impairment	$ 0	$ 0	$ 0	$ 0
Amortization of intangible assets	$ 1.7	$ 0.8	$ 3.3	$ 1.7

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Carrying Amounts of Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 46,756		$ 46,386
Accumulated Amortization	(9,029)		(5,716)
Net Carrying Amount	$ 37,727		40,670
Weighted-Average Remaining Useful Life	6 years 7 months 6 days	7 years 1 month 6 days
Goodwill	$ 73,732		68,019
Auto & Home
Finite-Lived Intangible Assets [Line Items]
Goodwill	5,364		5,364
Senior
Finite-Lived Intangible Assets [Line Items]
Goodwill	68,368		62,655
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	17,492		17,122
Accumulated Amortization	(4,817)		(3,448)
Net Carrying Amount	12,675		13,674
Trade Name
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	2,680		2,680
Accumulated Amortization	(893)		(625)
Net Carrying Amount	1,787		2,055
Proprietary Software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,592		1,592
Accumulated Amortization	(601)		(382)
Net Carrying Amount	991		1,210
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,292		1,292
Accumulated Amortization	(303)		(163)
Net Carrying Amount	989		1,129
Vendor relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	23,700		23,700
Accumulated Amortization	(2,415)		(1,098)
Net Carrying Amount	$ 21,285		$ 22,602

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Goodwill Rollforward (Details) $ in Thousands	6 Months Ended
	Dec. 31, 2021USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 68,019
Goodwill from the acquisition	5,713
Ending balance	$ 73,732

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Schedule of Future Amortization (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	$ 3,356
2023	6,166
2024	6,016
2025	5,746
2026	5,080
Thereafter	11,363
Net Carrying Amount	37,727	$ 40,670
Trade Name
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	268
2023	536
2024	536
2025	447
2026	0
Thereafter	0
Net Carrying Amount	1,787	2,055
Proprietary Software
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	214
2023	339
2024	308
2025	130
2026	0
Thereafter	0
Net Carrying Amount	991	1,210
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	142
2023	273
2024	220
2025	220
2026	134
Thereafter	0
Net Carrying Amount	989	1,129
Vendor relationships
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	1,317
2023	2,633
2024	2,633
2025	2,633
2026	2,633
Thereafter	9,436
Net Carrying Amount	21,285	22,602
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Remainder fiscal 2022	1,415
2023	2,385
2024	2,319
2025	2,316
2026	2,313
Thereafter	1,927
Net Carrying Amount	$ 12,675	$ 13,674

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands	6 Months Ended
	Dec. 31, 2021USD ($)
Lessee, Lease, Description [Line Items]
Expected rental payments	$ 57,494
Lessee, Operating Lease, Lease Not yet Commenced, Amount	3,500
Monaca, Pennsylvania | Affiliated Entity
Lessee, Lease, Description [Line Items]
Expected rental payments	$ 3,600
Operating lease, term	10 years
Option to extend	5 years
Minimum
Lessee, Lease, Description [Line Items]
Operating lease, term	1 year
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	7 years
Maximum
Lessee, Lease, Description [Line Items]
Operating lease, term	14 years
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	10 years

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Finance lease costs	$ 42	$ 58	$ 84	$ 125
Operating lease costs	2,048	1,952	4,058	3,879
Short-term lease costs	15	58	28	125
Variable lease costs	256	449	469	714
Sublease income	(128)	(170)	(465)	(235)
Total net lease costs	$ 2,233	$ 2,347	$ 4,174	$ 4,608

Leases - Maturity of Lease Liab

Leases - Maturity of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2021USD ($)
Operating leases
Remainder fiscal 2022	$ 4,552
2023	8,861
2024	9,237
2025	9,254
2026	7,040
2027	5,666
Thereafter	12,884
Total undiscounted lease payments	57,494
Less: interest	15,292
Present value of lease liabilities	42,202
Finance leases
Remainder fiscal 2022	97
2023	27
2024	0
2025	0
2026	0
2027	0
Thereafter	0
Total undiscounted lease payments	124
Less: interest	2
Present value of lease liabilities	122
Remainder fiscal 2022	4,649
2023	8,888
2024	9,237
2025	9,254
2026	7,040
2027	5,666
Thereafter	12,884
Total undiscounted lease payments	57,618
Less: interest	15,294
Present value of lease liabilities	$ 42,324

Debt - Credit Agreement and Sen

Debt - Credit Agreement and Senior Secured Credit Facility (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Jun. 30, 2021
Debt Instrument [Line Items]
Unamortized debt issuance costs on Term Loans	$ (3,469)	$ (4,081)
Unamortized debt discount on Term Loans	(5,924)	(6,428)
Total debt	707,519	461,403
Less current portion of debt	(7,169)	(2,360)
Non-current portion of debt	700,350	459,043
Line of Credit | Secured Debt
Debt Instrument [Line Items]
Loans outstanding	$ 471,912	$ 471,912

Debt - Narrative (Details)

Debt - Narrative (Details)	Dec. 22, 2021USD ($)	Nov. 05, 2019USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Feb. 07, 2022USD ($)	Dec. 23, 2021USD ($)	Nov. 02, 2021USD ($)lender	Jun. 30, 2021USD ($)	Feb. 24, 2021USD ($)	May 29, 2020USD ($)
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity									$ 75,000,000
Net proceeds from Term Loans					$ 242,000,000	$ 0
Unamortized debt discount on Term Loans			$ 5,924,000		5,924,000					$ 6,428,000
Unamortized debt issuance costs			22,900,000		22,900,000
Debt issuance costs and debt discounts			27,100,000
Amortization of debt issuance costs			2,100,000	$ 800,000	3,000,000	$ 1,600,000
Cash flow hedge to be reclassified during next 12 months			$ 600,000		$ 600,000
Interest Rate Swap
Line of Credit Facility [Line Items]
Derivative, notional amount												$ 325,000,000
Base Rate | Interest Rate Swap
Line of Credit Facility [Line Items]
Derivative, basis spread on variable rate			1.03%		1.03%
Line of Credit | LIBOR
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		5.00%
LIBOR floor rate		0.75%
Line of Credit | Base Rate
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		4.00%
Revolving Credit Facility | LIBOR
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		4.00%
Revolving Credit Facility | Base Rate
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate		3.00%
Secured Debt | Line of Credit | Term Loans
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity		$ 656,000,000
Net proceeds from Term Loans	$ 245,000,000
Debt instrument, periodic payment, percent		1.00%
Secured Debt | Line of Credit | DDTL Facility
Line of Credit Facility [Line Items]
Increase to maximum borrowing capacity									200,000,000
Line of credit facility, maximum borrowing capacity			$ 345,000,000		$ 345,000,000						$ 145,000,000
Term loans outstanding			$ 245,000,000		$ 245,000,000					0
Unamortized debt discount on Term Loans									$ 3,000,000
Number of lenders | lender									2
Unamortized debt issuance costs								$ 300,000	$ 1,200,000
Ticking fee multiplier, fee					1.00%
Debt instrument, periodic payment, percent					0.25%
Borrowing covenants time restricted capacity									100,000,000
Secured Debt | Line of Credit | DDTL Facility | Subsequent Event
Line of Credit Facility [Line Items]
Remaining borrowing capacity							$ 100,000,000
Secured Debt | Revolving Credit Facility
Line of Credit Facility [Line Items]
Commitment fee percentage		0.15%
Line of Credit | Base Rate | Interest Rate Swap
Line of Credit Facility [Line Items]
Derivative, fixed interest rate			5.00%		5.00%
Line of Credit | Revolving Credit Facility
Line of Credit Facility [Line Items]
Increase to maximum borrowing capacity								35,000,000	$ 25,000,000
Line of credit facility, maximum borrowing capacity								$ 135,000,000
Line of Credit | Revolving Credit Facility | Subsequent Event
Line of Credit Facility [Line Items]
Remaining borrowing capacity							$ 135,000,000
Line of Credit | Secured Debt
Line of Credit Facility [Line Items]
Increase to maximum borrowing capacity											231,000,000
Line of credit facility, maximum borrowing capacity											$ 425,000,000
Term loans outstanding			$ 471,912,000		$ 471,912,000					$ 471,912,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - West Palm Beach Police Pension Fund v. SelectQuote, Inc.	Oct. 07, 2021defendant
Executive Officer
Commitments and Contingencies Disclosure [Abstract]
Number of defendants	2
Loss Contingencies [Line Items]
Number of defendants	2
Current and Former Director
Commitments and Contingencies Disclosure [Abstract]
Number of defendants	6
Loss Contingencies [Line Items]
Number of defendants	6

Shareholders' Equity - Common S

Shareholders' Equity - Common Stock Reserved For Future Issuance (Details) - shares	Dec. 31, 2021	Jun. 30, 2021
Class of Stock [Line Items]
Options issued and outstanding under stock option plans (in shares)	4,278,864	3,398,513
Common Stock
Class of Stock [Line Items]
Number of shares available for grant (in shares)	17,296,284
Employee Stock Purchase Plan ("ESPP") | Common Stock
Class of Stock [Line Items]
Number of shares available for grant (in shares)	1,253,575
2020 Plan | Common Stock
Class of Stock [Line Items]
Number of shares available for grant (in shares)	10,721,627
Options issued and outstanding under stock option plans (in shares)	3,603,818
2003 Plan | Common Stock
Class of Stock [Line Items]
Options issued and outstanding under stock option plans (in shares)	1,717,264

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Share-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Share-based compensation expense	$ 1,706	$ 1,194	$ 3,791	$ 2,100
Incentive Stock Options
Class of Stock [Line Items]
Share-based compensation expense	884	455	1,624	818
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Share-based compensation expense	1,127	545	2,080	960
Performance Stock (PSUs)
Class of Stock [Line Items]
Share-based compensation expense	$ (305)	$ 194	$ 87	$ 322

Shareholders' Equity - Fair Val

Shareholders' Equity - Fair Value Assumptions (Details) - $ / shares	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Volatility	30.20%	25.00%
Risk-free interest rate	0.90%	0.40%
Dividend yield	0.00%	0.00%
Assumed forfeitures	0.00%	0.00%
Expected term (in years)	6 years 3 months	6 years 2 months 26 days
Weighted-average fair value (in dollars per share)	$ 5.52	$ 4.86

Shareholders' Equity - Option A

Shareholders' Equity - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Dec. 31, 2021
Number of Options
Beginning balance (in shares)	3,398,513
Options granted (in shares)	1,254,089
Options exercised (in shares)	(339,670)
Options forfeited/expired/cancelled (in shares)	(34,068)
Ending balance (in shares)	4,278,864
Vested and exercisable, number of options (in shares)	2,009,390
Weighted- Average Exercise Price
Beginning balance (in dollars per share)	$ 8.60
Options granted (in dollars per share)	17.61
Options exercised (in dollars per share)	3.81
Options forfeited/expired/cancelled (in dollars per share)	17.12
Ending balance (in dollars per share)	11.54
Vested and exercisable, weighted average exercise price (in dollars per share)	$ 3.89
Weighted-average remaining contractual term, outstanding	6 years 9 months 10 days
Weighted-average remaining contractual term, vested and exercisable	4 years 1 month 28 days
Aggregate intrinsic value, outstanding	$ 13,904
Aggregate intrinsic value, vested and exercisable	$ 13,759

Shareholders' Equity - Share-Ba

Shareholders' Equity - Share-Based Compensation Plans (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Cost not yet recognized	$ 10,200		$ 10,200
Cost not yet recognized, period for recognition			3 years 1 month 6 days
Proceeds from common stock options exercised and employee stock purchase plan	$ 100	$ 100	$ 2,271	$ 391

Shareholders' Equity - Restrict

Shareholders' Equity - Restricted Stock Unit and Performance Stock Activity (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Dec. 31, 2021
Restricted Stock Units (RSUs)
Number of Restricted Stock Units
Beginning balance (in shares)	356,285
Granted (in shares)	453,679
Vested (in shares)	(82,689)
Cancelled (in shares)	(14,058)
Ending balance (in shares)	713,217
Weighted-Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 19.12
Granted (in dollars per share)	16.78
Vested (in dollars per share)	19.61
Cancelled (in dollars per share)	17.84
Ending balance (in dollars per share)	$ 17.61
Share-based cost not yet recognized	$ 10.7
Weighted-average remaining service period	2 years 11 months 15 days
Performance Stock
Number of Restricted Stock Units
Beginning balance (in shares)	132,921
Granted (in shares)	196,080
Vested (in shares)	0
Performance adjustment (in shares)	(164,500)
Cancelled (in shares)	0
Ending balance (in shares)	164,501
Weighted-Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 17.97
Granted (in dollars per share)	17.80
Vested (in dollars per share)	0
Cancelled (in dollars per share)	0
Ending balance (in dollars per share)	$ 17.87
Share-based cost not yet recognized	$ 2.1
Weighted-average remaining service period	2 years 3 months 21 days
Award performance period	3 years
Performance Stock | Share-based Payment Arrangement, Tranche One | Minimum
Weighted-Average Grant Date Fair Value
Number of potential shares earned	0.00%
Performance Stock | Share-based Payment Arrangement, Tranche One | Maximum
Weighted-Average Grant Date Fair Value
Number of potential shares earned	150.00%
Performance Stock | Share-based Payment Arrangement, Tranche Two | Minimum
Weighted-Average Grant Date Fair Value
Number of potential shares earned	0.00%
Performance Stock | Share-based Payment Arrangement, Tranche Two | Maximum
Weighted-Average Grant Date Fair Value
Number of potential shares earned	200.00%

Shareholders' Equity - Employee

Shareholders' Equity - Employee Stock Purchase Plan (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share-based compensation expense	$ 1,894	$ 1,336	$ 4,109	$ 2,259
Employee Stock Purchase Plan ("ESPP") | Employee Stock Purchase Plan ("ESPP")
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Purchase price of common stock, percent			95.00%
Minimum purchase price of common stock as a percent of offering date fair value, percent			85.00%
Minimum purchase price of common stock as a percent of common stock exercise date fair value, percent			85.00%
Shares issued to employees (in shares)			89,985
Share-based compensation expense	$ 200	$ 100	$ 300	$ 100

Shareholders' Equity - Narrativ

Shareholders' Equity - Narrative (Details)	6 Months Ended
	Dec. 31, 2021planinstallmentshares
Class of Stock [Line Items]
Number of share-based compensation plans | plan	2
Common Stock
Class of Stock [Line Items]
Number of shares available for grant (in shares)	17,296,284
2003 Plan
Class of Stock [Line Items]
Award exercise period after termination	90 days
Award exercise period after termination due to death or disability	12 months
Award expiration period	10 years
Number of installments | installment	4
Purchase price of common stock, percent	100.00%
2003 Plan | Share-based Payment Arrangement, Tranche One
Class of Stock [Line Items]
Vesting rights percentage	33.30%
2003 Plan | Share-based Payment Arrangement, Tranche Two
Class of Stock [Line Items]
Vesting rights percentage	0.0416%
2020 Plan
Class of Stock [Line Items]
Percentage of outstanding stock annual increase, maximum	3.00%
2020 Plan | Common Stock
Class of Stock [Line Items]
Number of shares available for grant (in shares)	10,721,627
Incentive Stock Options | 2020 Plan
Class of Stock [Line Items]
Common stock, shares reserved for future issuance (in shares)	4,000,000

Revenue from Contracts with C_2

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 194,981	$ 157,526	$ 357,565	$ 352,508	$ 480,339
Marketing Development Funds
Disaggregation of Revenue [Line Items]
Unearned revenue	2,300			2,300
Commission
Disaggregation of Revenue [Line Items]
Total revenue	140,701	$ 132,254	320,265	272,956	425,415
Production bonus and other
Disaggregation of Revenue [Line Items]
Total revenue	54,280		37,300	79,552	54,924
Intersegment Eliminations
Disaggregation of Revenue [Line Items]
Total revenue	1,901		852	5,594	2,243
Intersegment Eliminations | Commission
Disaggregation of Revenue [Line Items]
Total revenue	1,168		280	2,810	465
Intersegment Eliminations | Production bonus and other
Disaggregation of Revenue [Line Items]
Total revenue	733		572	2,784	1,778
Senior
Disaggregation of Revenue [Line Items]
Total revenue	157,967		315,510	264,287	388,709
Senior | Commission
Disaggregation of Revenue [Line Items]
Total revenue	109,200		284,210	195,272	344,730
Senior | Medicare advantage
Disaggregation of Revenue [Line Items]
Total revenue	99,262		263,975	179,345	312,705
Senior | Medicare supplement
Disaggregation of Revenue [Line Items]
Total revenue	2,332		12,743	3,936	20,735
Senior | Prescription drug plan
Disaggregation of Revenue [Line Items]
Total revenue	732		1,102	1,001	1,717
Senior | Dental, vision, and health
Disaggregation of Revenue [Line Items]
Total revenue	4,920		5,647	8,136	8,370
Senior | Other commission revenue
Disaggregation of Revenue [Line Items]
Total revenue	1,954		743	2,854	1,203
Senior | Production bonus and other
Disaggregation of Revenue [Line Items]
Total revenue	48,767		31,300	69,015	43,979
Life
Disaggregation of Revenue [Line Items]
Total revenue	32,780		35,666	80,211	77,094
Life | Commission
Disaggregation of Revenue [Line Items]
Total revenue	27,012		29,844	67,845	66,046
Life | Term
Disaggregation of Revenue [Line Items]
Total revenue	16,126		20,028	32,372	39,772
Life | Final expense
Disaggregation of Revenue [Line Items]
Total revenue	10,886		9,816	35,473	26,274
Life | Production bonus and other
Disaggregation of Revenue [Line Items]
Total revenue	5,768		5,822	12,366	11,048
Auto & Home
Disaggregation of Revenue [Line Items]
Total revenue	6,135		7,241	13,604	16,779
Auto & Home | Commission
Disaggregation of Revenue [Line Items]
Total revenue	5,657		6,491	12,649	15,104
Auto & Home | Production bonus and other
Disaggregation of Revenue [Line Items]
Total revenue	$ 478		$ 750	$ 955	$ 1,675

Revenues from Contracts with _2

Revenues from Contracts with Customers - Commission Receivable Roll Forward (Details) $ in Thousands	6 Months Ended
	Dec. 31, 2021USD ($)
Activity in Commissions Receivable [Roll Forward]
Beginning balance	$ 845,897
Commission revenue from revenue recognized	212,976
Net commission revenue adjustment from change in estimate	(149,174)
Amounts recognized as accounts receivable	(23,894)
Ending balance	$ 885,805

Revenues from Contracts with _3

Revenues from Contracts with Customers - Narrative (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2021USD ($)
Disaggregation of Revenue [Line Items]
Net commission revenue adjustment from change in estimate		$ (149,174)
Medicare advantage | Senior
Disaggregation of Revenue [Line Items]
Net commission revenue adjustment from change in estimate		$ (145,000)
Medicare advantage | Senior | Fiscal Year 2021
Disaggregation of Revenue [Line Items]
Reduction in commission revenue	0.62
Medicare advantage | Senior | Fiscal Year 2020
Disaggregation of Revenue [Line Items]
Reduction in commission revenue	0.28
Medicare advantage | Senior | Fiscal Year 2019
Disaggregation of Revenue [Line Items]
Reduction in commission revenue	0.08

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (46,536)	$ (16,045)	$ 26,391	$ (62,580)	$ 24,994
Effective income tax rate reconciliation, percent	25.40%		22.70%	25.40%	21.80%

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net income (loss)	$ (137,008)	$ (47,153)	$ 89,856	$ (184,161)	$ 89,591
Net income (loss) attributable to common shareholders	$ (137,008)		$ 89,856	$ (184,161)	$ 89,591
Denominator:
Weighted average number of shares outstanding, basic (in shares)	163,966		162,645	163,829	162,546
Net income (loss) per share—basic: (in dollars per share)	$ (0.84)	$ (0.29)	$ 0.55	$ (1.12)	$ 0.55
Numerator:
Net income (loss) attributable to common shareholders	$ (137,008)		$ 89,856	$ (184,161)	$ 89,591
Net income (loss) attributable to common and common equivalent shareholders	$ (137,008)		$ 89,856	$ (184,161)	$ 89,591
Denominator:
Weighted average number of shares outstanding, basic (in shares)	163,966		162,645	163,829	162,546
Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP	0		2,918	0	2,831
Total common and common equivalent shares outstanding (in shares)	163,966		165,563	163,829	165,377
Net income (loss) per share—diluted: (in dollars per share)	$ (0.84)	$ (0.29)	$ 0.54	$ (1.12)	$ 0.54

Net Income (Loss) Per Share - A

Net Income (Loss) Per Share - Antidilutive Shares (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	5,298	0	5,155	0
Stock Option | Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	5,133	0	4,908	0
Stock Option | Phantom Share Units (PSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	165	0	247	0

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended			6 Months Ended
	Dec. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2021USD ($)segment	Dec. 31, 2020USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment				3
Revenue	$ 194,981	$ 157,526	$ 357,565	$ 352,508	$ 480,339
Operating expenses	(358,211)		(228,753)	(562,077)	(340,835)
Other expenses, net	(51)		(21)	(153)	(43)
Adjusted EBITDA	(163,281)		128,791	(209,722)	139,461
Share-based compensation expense	(1,894)		(1,336)	(4,109)	(2,259)
Non-recurring expenses	(1,602)		(362)	(2,155)	(822)
Fair value adjustments to contingent earnout obligations			(395)	0	(1,153)
Depreciation and amortization	(6,175)		(3,590)	(11,278)	(6,937)
Loss on disposal of property, equipment, and software	(5)		(79)	(355)	(162)
Interest expense, net	(10,587)		(6,782)	(19,122)	(13,543)
Income tax benefit	46,536	16,045	(26,391)	62,580	(24,994)
NET INCOME (LOSS)	(137,008)	$ (47,153)	89,856	(184,161)	89,591
Corp & Elims
Segment Reporting Information [Line Items]
Revenue	(1,901)		(852)	(5,594)	(2,243)
Operating expenses	(15,979)		(12,746)	(29,330)	(22,264)
Other expenses, net	(51)		(21)	(153)	(43)
Adjusted EBITDA	(17,931)		(13,619)	(35,077)	(24,550)
Salary expense	(11,200)		8,400	21,600	15,000
Professional fees	(4,300)		3,300	9,000	6,300
Senior
Segment Reporting Information [Line Items]
Revenue	$ 157,967		$ 315,510	$ 264,287	$ 388,709
Senior | Major Customer One | Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk, percentage	24.00%		30.00%	21.00%	27.00%
Senior | Major Customer Two | Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk, percentage	15.00%		22.00%	14.00%	20.00%
Senior | Major Customer Three | Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk, percentage			18.00%	13.00%	15.00%
Senior | Operating Segments
Segment Reporting Information [Line Items]
Revenue	$ 157,967		$ 315,510	$ 264,287	$ 388,709
Operating expenses	(306,602)		(180,955)	(445,893)	(245,252)
Other expenses, net	0		0	0	0
Adjusted EBITDA	(148,635)		134,555	(181,606)	143,457
Life
Segment Reporting Information [Line Items]
Revenue	$ 32,780		35,666	80,211	77,094
Life | Major Customer One | Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk, percentage	11.00%
Life | Operating Segments
Segment Reporting Information [Line Items]
Revenue	$ 32,780		35,666	80,211	77,094
Operating expenses	(30,930)		(29,961)	(76,058)	(62,307)
Other expenses, net	0		0	0	0
Adjusted EBITDA	1,850		5,705	4,153	14,787
Auto & Home
Segment Reporting Information [Line Items]
Revenue	6,135		7,241	13,604	16,779
Auto & Home | Operating Segments
Segment Reporting Information [Line Items]
Revenue	6,135		7,241	13,604	16,779
Operating expenses	(4,700)		(5,091)	(10,796)	(11,012)
Other expenses, net	0		0	0	0
Adjusted EBITDA	$ 1,435		$ 2,150	$ 2,808	$ 5,767